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4Abstract
Background
Type 2 diabetes (T2DM) is a strong risk factor for coronary heart disease (CHD). A great many diabetic 
subjects suffer from congestive heart failure (CHF), a condition with a high concomitant mortality. So far, 
attempts aimed at reducing macrovascular complications in T2DM have been essentially futile. Hence, there 
is a need for finding glucose-lowering agents that exert direct positive effects on vasculature and the heart. 
Glucagon-like peptide-1(GLP-1) is a peptide secreted from the L-cells in the small intestine. GLP-1 decreases 
plasma glucose by increasing insulin secretion without an increased risk for hypoglycemia. 
Aims
The aim of this work was to evaluate the putative role and potential effects of GLP-1 and related peptides on 
the vasculature and heart and to elucidate the mechanisms behind these effects.  
Study I and II
These papers are based on studies performed within the ULSAM (Uppsala longitudinal study of adult men) 
cohort, a community-based prospective cohort study of elderly men started in 1970. The participants were 
examined at age 50 and 70 and the data was completed with annual updates on mortality and morbidity. The 
examination at age 70 forms the baseline of the present studies. A subsample from this cohort consisting of 
509 men performed an oral glucose tolerance test (OGTT), plasma samples were stored frozen and GLP-1 
concentrations were analyzed in 2007. At baseline, echocardiographic measurements of left ventricular func-
tion were done. Information concerning incident disease was collected from official Swedish registries. The 
studies did not reveal any longitudinal associations between plasma GLP-1 levels and the incidence of CHD 
or CHF. Cross-sectionally, however, we found correlative associations between plasma GLP-1 levels and im-
paired glucose tolerance and diastolic cardiac dysfunction.
Study III
This was a double-blinded randomized cross-over study. Twenty patients with T2DM hospitalized for de-
compensated congestive heart failure (CHF) were enrolled in the study. Primary outcome was the propor-
tion of subjects achieving a 20% increase of cardiac index (CI) and a 20% decrease of pulmonary capillary 
wedge pressure (PCWP), i.v. infusions with exenatide or placebo, 18 hours apart. Hemodynamic variables 
were monitored by heart catheterization. Exenatide evoked a 21% increase in CI, a 29% increase of heart rate, 
a 15% decrease of PCWP and a 17% decrease of right atrial pressure. 
Study IV
The aim of this study was to investigate whether exenatide could protect against endothelial dysfunction in-
duced by lipotoxicity and if there were any differences in vasorelaxant capacity between GLP-1 (7-36), the 
degradation metabolite GLP-1 (9-36) and exenatide in femoral arterial rings from non-diabetic rats ex vivo. 
Exenatide did not protect against lipotoxicity, whereas GLP-1 (7-36) and GLP-1 (9-36) exerted vasorelaxation 
with 23% and 38%, respectively, vs. only 3% with exenatide.
Study V
We studied the effects of exenatide, GLP-1 (7-36) and GLP-1 (9-36) on human coronary artery endothelial 
cell (HCAEC) proliferation and potential underlying mechanisms. Exenatide, GLP-1 (7-36) and GLP-1(9-36) 
elicited dose-dependent increases in DNA synthesis and increased cell numbers. This was associated with en-
hanced eNOS and Akt activity, which – along with the augmented cell proliferation - were inhibited by PKA-, 
PI3K-, Akt- and eNOS-inhibitors and by a GLP-1 receptor antagonist. 
Conclusions
Altered plasma GLP-1 levels were not found to predict incident CHD or CHF, while significant cross-sectional 
correlations were found between GLP-1 impaired glucose tolerance (IGT) and diastolic cardiac function in 
elderly men. GLP-1 and related peptides stimulate proliferation of HCAEC cells, exert vasorelaxant effects on 
rat arterial rings ex vivo and evoke potent hemodynamic effects in T2DM patients with CHF. These effects 
seem to occur independent of changes in glucose concentrations. These findings prompt further efforts and 
mechanistic studies aimed at characterizing potential beneficial cardiovascular effects of incretin hormones in 
the clinical management of T2DM patients.
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Diabetes is considered by the WHO as one 
of the major threats to human health in 
the 21st century [1] and the latest estimate 
by the WHO (2000) gives that 171 million 
people worldwide currently suffer from 
diabetes and that this number will increase 
to 366 million in 2030 [2]. Cardiovascular 
disease (CVD) is by far the most common 
complication of diabetes (T2DM). Suffer-
ing from diabetes does not only signifi-
cantly increase the risk of CVD but is also 
associated with poor survival, both acutely 
and in the long term, after a myocardial 
infarction (MI) [3]. In fact, total mortal-
ity from coronary heart disease (CHD) in 
subjects with diabetes without a previous 
MI is as high as that of non-diabetic indi-
viduals with a previous MI [4]. 
Congestive heart failure (CHF) is a 
clinical syndrome with high coexistant 
morbidity and mortality. In a population 
based study from Reykjavik, Thrainsdottir 
et al found a prevalence of 11.8% of heart 
failure in patients with diabetes, compared 
to 3.2% in control subjects [5]. The preva-
lence of diabetes in CHF amounts to ~ 20 
- 35% [6]. 
Regardless of the risk factors involved, 
atherosclerosis is perceived as much of an 
inflammatory disease in which endothe-
lial dysfunction plays an essential role at 
all stages of the atherosclerotic process 
[7-12].
 Endothelial dysfunction is commonly 
observed in association with T2DM and 
other situations characterized by insulin 
resistance, and is related to a heightened 
risk for initial or recurrent cardiovascu-
lar malfunction [13-15]. Although the 
hypothesis that specifically reversing en-
dothelial dysfunction can reduce the risk 
for CVD has not been tested directly, many 
different alterations in lifestyle [16-18] and 
pharmacological interventions designed to 
improve endothelial function are known 
to lower this risk [19-21]. The traditional 
“glucocentric” approach, i.e. to focus solely 
on the treatment of the hyperglycemia, has 
failed to reduce the incidence of CVD [22-
24]. In fact, there is strong evidence for 
the efficacy of the multifactorial approach 
[20, 21]. So far, no particular antidiabetic 
treatment has proven superior to other 
hypoglycemic agents in reducing CVD 
risk so there is a clear need to identify new 
weapons of the pharmacologic armamen-
tarium that positively impact the endothe-
lium and cardiovascular system
There is today a growing body of 
evidence that Glucagon-Like-Peptide-1 
(GLP-1) might have a beneficial role in 
cardiovascular function beside its well 
known antihyperglycemic action [25, 26].
 To this end, the over-arching aim of 
this thesis was to explore the potential ef-
fects of GLP-1 and related peptides on the 
endothelium, vasculature and the heart 
and to reveal underlying mechanisms of 
these effects in a translational research set-
ting.      
Diabetes mellitus
The origin of the word “diabetes” is the 
Greek word for siphon. The Greek physi-
cian Aretus found that some patients had 
a marked polyuria - and that water in 
these patients - passed like in a siphon. He 
named the condition Diabetes. 
Diabetes mellitus is a disease associated 
with hyperglycemia. Diabetes can be 
caused by two principal mechanisms:
1. Inadequate production of insulin. 
2. Inadequate sensitivity of cells to the 
10
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action of insulin.
The two main types of diabetes that 
correspond to these two mechanisms are 
called type 1 diabetes  mellitus (T1DM) 
and type 2 diabetes mellitus (T2DM). 
T1DM is characterized by a marked de-
crease in insulin production, a subacute 
onset of hyperglycemia and is ketosis 
prone. T2DM is characterized by an adult 
onset of hyperinsulinemia and decreas-
ing insulin sensitivity, a slow progression 
of hyperglycemia and is associated with 
obesity. T2DM is accounting for approxi-
mately 90% of all cases of diabetes [1].
Both T1DM and T2DM are independ-
ent risk factors for CVD [4, 27, 28]. This 
thesis will only deal with T2DM and con-
sequently, T2DM is herein referred to, as 
“diabetes”.
Definitions 
The hyperglycemic conditions impaired 
glucose tolerance (IGT), impaired fast-
ing glucose (IFG) and diabetes are simply 
defined according to the degree of hyper-
glycemia. IGT is defined as a moderate el-
evated postprandial glucose concentration 
determined by an oral glucose tolerance 
Classification criteria (mmol/l)Glucometabolic state
Normal glucose tolerance FPG < 6.1 and 2hPG < 7.8 
Impaired glucose tolerance FPG < 7.0 and 2hPG ≥7.8 and ≤ 11.1
Impaired fasting glucose FPG ≥ 6.1 and < 7.0 and 2hPG < 7.8
Diabetes mellitus FPG ≥ 7.0 or 2hPG ≥ 11.1
Table 1. Definitions of normoglycemia and different states of glucose abnormalities ac-
cording to the WHO in 2005 (venous plasma glucose).
test (OGTT). IFG is defined as isolated 
moderate elevated fasting glucose and dia-
betes is defined as elevated fasting glucose 
or elevated postprandial (OGTT). IGT 
and IFG are associated with an increased 
risk of developing diabetes and CVD [1, 
29, 30]. 
The currently used criteria for gluco-
metabolic classification according to the 
WHO [31] are presented in Table 1.  
T2DM
Estimations by the WHO and the inter-
national diabetes federation (IDF) gives a 
prevalence of diabetes in 5.1% of the adult 
population. In addition, it is likely that 
these numbers will be matched or exceed-
ed by subjects with IGT and IFG, which 
both are dysglycemic states that currently 
affect approximately 8% of adults world-
wide [32]. In total approximately 13% 
of the global adult population therefore 
suffer from abnormalities in glucose me-
tabolism. T2DM is characterized by an in-
creasing insulin resistance and decreasing 
β-cell function and eventually also loss of 
β-cell mass [33-36].
Introduction
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Insulin resistance
Insulin resistance is usually defined as 
an abnormal glucose turnover in the face 
of normal or raised glucose and insulin 
concentrations. Insulin sensitivity is de-
termined not only by the number and af-
finity of the insulin receptors, but also by 
the functional state of the intracellular 
signaling pathways that transduce insulin 
binding to various downstream effectors 
e.g. glucose transport, phosphorylation 
and oxidation, glycogen synthesis, lipoly-
sis and ion exchange [37]. Cellular resist-
ance of the glucose metabolic pathway 
is caused by a dysfunction of the signal 
transduction machinery. The various insu-
lin effectors are, at least in part, independ-
ent of one another. As a consequence, cel-
lular insulin resistance can vary in degree 
and pathway specificity. To the extent that 
they have preserved their sensitivity, oth-
er pathways may be overly stimulated by 
the compensatory hyperinsulinemia. The 
pathophysiologic implication of this phe-
nomenon is that, in insulin resistant states, 
any abnormality that is found to be associ-
ated with altered glucose metabolism e.g. 
dyslipidemia, hypertension, platelet hy-
percoagulation, or prothrombotic changes 
theoretically can be the result of either the 
insulin resistance per se or the chronic ef-
fects of the attendant hyperinsulinemia 
[37]. Zethelius et al. found that proinsulin 
is a strong predictor of CHD independent 
of other major risk factors as smoking, ele-
vated blood pressure and serum cholester-
ol concentrations whereas insulin does not 
seem to be a predictor of CHD. Although 
rather than being directly associated with 
its cause, proinsulin may be a marker of an 
underlying metabolic disturbance predis-
posing to atherosclerosis [38]. 
There is strong evidence for the associa-
tion between inflammation and insulin re-
sistance and links of these features to CVD 
[12]. Epidemiologic studies show strong 
correlation between proinflammatory bi-
omarkers, e.g. CRP, interleukin 6, and tu-
mor necrosis factor and perturbations in 
glucose homoeostasis and arteriosclerosis 
[39]. Moreover, alterations in CRP con-
centrations might be independently asso-
ciated with insulin resistance [40, 41]. In 
recent years, numerous studies have been 
published that link subclinical chronic in-
flammation to the development of insulin 
resistance and T2DM [12].
The metabolic syndrome
The ‘metabolic syndrome’, as we currently 
know it, was born as ‘the insulin resistance 
syndrome’. In 1988, Reaven [42] formal-
ized the concept that insulin resistance 
clusters with glucose intolerance, dyslipi-
demia and hypertension to heighten cardi-
ovascular risk. The definition by the WHO 
of the metabolic syndrome is based on any 
sign of insulin resistance, i.e. IGT, IFG or 
diabetes, together with two or more of the 
components hypertension, hypertriglycer-
idemia, low HDL cholesterol, central obes-
ity and microalbuminuria. The syndrome 
is clearly overrepresented among T2DM 
subjects [43, 44].  
T2DM and CVD
CHD is a dominant cause of mortality 
and morbidity in the industrialized world 
[45]. The underlying state, atherosclerosis, 
is a progressive process starting early in 
life and silently proceeding during many 
years. T2DM is an independent risk factor 
for developing CHD, and the risk of CHD 
or stroke is up to four times higher in pa-
tients with diabetes compared to non-di-
abetic subjects [4]. T2DM, hypertension 
and dyslipidemia are all states associated 
with insulin resistance and an increased 
risk for CHD (figure 1) [46, 47]. The preva-
Introduction
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lence of diabetes in patients with acute MI 
is high, approximately 30%, and is further 
increased in older populations [48, 49]. 
Results from a large Finnish database 
showed that for every 1% increase of 
HbA1c, CVD mortality increased by about 
10% in T2DM [50]. The United Kingdom 
prospective diabetes study (UKPDS), a 
large cohort of newly diagnosed people 
with T2DM, indicated a 16% increased 
risk of MI for every unit (%) increase of 
HbA1c [51]. A global meta-analysis of all 
available epidemiological data for mortal-
ity from ischemic heart disease in relation 
to FPG has demonstrated an overall in-
crease of 20 % for every 1 mmol/l increase 
of FPG above the optimum level [52]. In 
fact,  the concentration of a single, random 
blood glucose measurement in the acute 
phase of macrovascular complications, 
for example, acute MI, was found highly 
Figure 1. Contributing risk factors for coronary heart disease (CHD).  
IGT: impaired glucose tolerance, IFG: impaired fasting glucose, IR: insulin resistance, ED: en-
dothelial dysfunction, CHD: coronary heart disease.
Dyslipidemia
Hypertension
IR
Inammation                   ED                     Atherosclerosis
IGT
CHD
IFG
Diabetes
predictive whenever investigated, both for 
short-term prognosis during hospital stay 
and long term over several years [53].
The endothelium
The endothelium consists of a single layer 
of cells that line all the vessels in the body. 
These cells provide an interface between 
the blood and the tissues. The endothe-
lium is known to work in an autocrine, 
paracrine and endocrine manner and is 
proposed to be involved in multiple func-
tions, including maintenance of vascular 
tone, coagulation, fibrinolysis, and platelet 
and leukocyte adherence [11, 54, 55]. The 
interplay between endothelium and vessel 
is dependent on type and location of the 
vessel, i.e. in conduit arteries endothelial 
cells limit the activation of clotting and 
pro-inflammatory factors, in resistance 
Introduction Introduction
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vessels they contribute to the regulation 
of blood flow, and in precapillary arteri-
oles the endothelium transports and dis-
tributes nutrients and hormones. Almost 
three decades ago, Furchgott and Zawadz-
ki demonstrated the important role of the 
endothelium in vasodilator activity [56]. 
This vasodilator effect was demonstrated 
to be mediated by the endothelium-de-
rived relaxing factor (EDRF), subsequent-
ly identified as nitric oxide (NO), the key 
vasodilator factor in the endothelium [57]. 
Endothelial cells (EC) constitutively ex-
press NO synthase (eNOS) that generates 
NO using L-arginine as a substrate togeth-
er with FAD, FMN, NADPH and tetrahy-
drobiopterin as cofactors (figure 2) [57]. 
NO rapidly diffuses into vascular smooth 
muscle cells and binds to soluble guanylate 
cyclase. This event results in formation of 
cyclic GMP (cGMP), activating a cGMP-
dependent protein kinase. This leads to in-
hibition of the contractile machinery and 
thus vasodilatation [58]. Several different 
agonists releasing NO via receptor-oper-
ated mechanisms have been recognized, 
such as acetylcholine (ACh), bradykinin, 
serotonin and prostacyclin (PGI2) [59]. 
Besides the potent vasodilator effect of 
NO, it mediates many other protective 
functions in the endothelium. NO inhib-
its the expression of pro-inflammatory 
cytokines, chemokines and leukocyte ad-
hesion molecules, thereby limiting vascu-
Figure 2. The nitric oxide pathway in the vasculature.  
Endothelial cells constitutively expressing nitric oxide synthase (eNOS) generate NO using 
l-arginine as a substrate together with certain cofactors. NO then rapidly diffuses into vascular 
smooth muscle cells and binds to guanylate cyclase. This event results in formation of cyclic 
GMP (cGMP), activating a cGMP-dependent protein kinase, which leads to an increased extru-
sion of Ca2+ from the cytosol inhibiting the contractile machinery and thereby evoking va-
sodilation. Reprinted from Molecular and Cellular Endocrinology, 297, Nathanson D., Nyström, 
T., Hypoglycemic pharmacological treatment of type 2 diabetes: Targeting the endothelium, 
page no. 114, ©  (2009), with permission from Elsevier.
Bradykinin
Serotonin
L-citrullineL-arginine
NO
ACh SNP
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lar recruitment of leukocytes and platelets 
[60]. It also inhibits vascular smooth mus-
cle cell (VSMC) proliferation, an early sign 
of atherosclerosis [60].
Diabetes and endothelial dys-
function 
Endothelial dysfunction is a common fea-
ture in T2DM patients and in individu-
als with insulin resistant conditions [19]. 
Endothelial dysfunction can occur at any 
level in the arterial system and is a risk fac-
tor for the development of atherosclerosis 
[19]. In the healthy endothelium, there is 
an appropriate balance between vasodila-
tation and vasoconstriction. As mentioned 
above, NO is a key factor in regulating vas-
cular tone, e.g., vasodilatation. There are 
also antagonizing factors promoting vaso-
constrictor effects in the vasculature. The 
main vasoconstrictor factor is believed 
to be endothelin-1 (ET-1). The chain of 
processes that leads from endothelial dys-
function to atherosclerosis refers to an im-
balance in the production between these 
mediators, which may disrupt endothelial 
homeostasis and predispose the endothe-
lium to a pro-thrombotic and pro-ather-
ogenic milieu [59]. Although the molecu-
lar basis of endothelial dysfunction is not 
completely understood, numerous studies 
point to loss of NO biological activity and/
or biosynthesis as a culprit lesion [61]. In 
the presence of suboptimal concentrations 
of substrate or cofactors for the synthesis 
of NO, eNOS can become uncoupled. This 
results in the production of reactive oxy-
gen species (ROS), e.g. superoxide anion 
and hydrogen peroxide, an event com-
monly referred to as oxidative stress [62]. 
Evidence for the hypothesis that en-
dothelial dysfunction can precede diabetes 
is the finding of impaired vascular reactiv-
ity in subjects with normal glucose toler-
ance and with a family history of diabetes 
[63]. Endothelial dysfunction in subjects 
with T2DM seems to be multifactorial; hy-
pertension, dyslipidemia, obesity, micro-
albuminuria, low grade inflammation, hy-
perglycemia and impaired insulin effects 
(insulin resistance) on the endothelium 
have all been associated with endothelial 
dysfunction [19]. 
The heart
Physiology 
During the cardiac cycle, blood continu-
ously flows from the inferior vena cava/
superior vena cava and coronary sinus 
to the right atrium, and from the pulmo-
nary veins into the left atrium [64]. As 
atrial pressure increases, blood is pushed 
into the ventricle through the open atrio 
-ventricular (AV) valve. As the ventricles 
contract, the pressure builds up rapidly 
and causes closure of the AV valves. The 
pressure continues to rise rapidly against 
closed valves. This is often referred to as is-
ovolumetric ventricular contraction [64]. 
When ventricular pressure exceeds arterial 
pressure, the pulmonary and aortic valves 
open and blood is ejected into the arteries. 
Approximately 60% of the blood is ejected 
by a healthy left ventricle, i.e. the ejection 
fraction [64]. As the muscles relax, the 
pressure in the ventricles falls (known as 
the isovolumetric ventricular relaxation). 
When ventricular pressure is less than the 
atrial pressure, the AV valves open and 
the aortic and pulmonary valves close. 
Pressure is the product of flow and resist-
ance. Cardiac output (CO) is the amount 
of blood ejected from the left ventricle into 
the aorta each minute and the rate of CO 
is determined both by stroke volume and 
heart rate [64]. 
Introduction Introduction
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Ischemic heart disease
Ischemic heart disease (IHD), or myo-
cardial ischemia, is a disease usually due 
to coronary artery disease (CAD). Tradi-
tional risk factors for IHD and MI include 
positive family history, increasing age, hy-
pertension, dyslipidemia, cigarette smok-
ing, marked obesity, physical inactivity and 
diabetes [45]. CAD is the leading cause of 
death in the Western world [45]. Manifes-
tations of stable ischemic heart disease in-
clude angina and decreased exercise toler-
ance. Unstable IHD typically presents with 
central chest pain or other symptoms at 
rest, or rapidly worsening effort angina. In 
2000, the European Society of Cardiology 
(ESC) and the American College of Car-
diology (ACC) recommended a new defi-
nition for MI [65] that combines ischemic 
symptoms with changes in the ECG and in 
biochemical markers of myocardial necro-
sis and emphasizes the use of troponins.
Heart failure
Congestive heart failure (CHF) is a patho-
physiological state in which an abnormal-
ity of cardiac function is responsible for 
the failure of the heart to pump blood at a 
rate corresponding with the requirements 
of the metabolizing tissues. CHF is com-
monly described as a syndrome caused by 
cardiac dysfunction, and recognized by a 
constellation of signs and symptoms. Es-
timates of the prevalence of symptomatic 
CHF in the general European population 
range from 0.4 to 2% [66]. The prevalence 
of heart failure increases rapidly with age, 
with the mean age of the heart failure pop-
ulation being 74 years [66]. As the propor-
tion of the population that is elderly is in-
creasing, this partly accounts for the rising 
prevalence of heart failure. In Europe, my-
ocardial dysfunction secondary to CAD, 
usually as a consequence of MI, is the most 
common cause of heart failure among pa-
tients under 75 years [67] of age and clear 
abnormalities in systolic function are usu-
ally present. Systolic hypertension and car-
diac hypertrophy, cell loss and fibrosis may 
be more important causes of heart failure 
in the elderly and may be more likely to 
manifest predominantly as abnormalities 
of diastolic function [66]. Valvular abnor-
malities, diabetes and insulin resistance 
are also independent risk factors for CHF 
[66, 68, 69].
Cardiac metabolism 
The capacity of the human heart to oxi-
dize fat and carbohydrates is of great im-
portance. In a series of enzyme-catalyzed 
reactions, the heart converts chemical 
energy into mechanical energy [70, 71]. 
The human heart uses several kilograms 
of ATP as an energy source every day [70, 
71] . In a classic series of studies, Randle et 
al. demonstrated that fatty acids compete 
with glucose for substrate oxidation in iso-
lated rat heart muscle and rat diaphragm 
muscle. They speculated that increased fat 
oxidation causes the insulin resistance as-
sociated with obesity, diabetes and starva-
tion [72-74]. 
When the heart is acutely stressed, it is 
able to switch from fat to carbohydrate as 
fuel for oxidative energy production (fig-
ure 2) [75]. The advantage of increased 
carbohydrate oxidation relate to a higher 
effective value for the ratio of ATP syn-
thesized/O2 consumed for carbohydrate 
vs. lipid [75]. Furthermore, if the heart is 
exposed to changes in ventricular pres-
sures it reactivates its fetal gene program 
[71, 76]. Reactivation of these fetal genes 
includes a switch from fat to glucose oxi-
dation [77], which though initially adap-
tive, ultimately results in a loss of insulin 
sensitivity and hence, a loss of metabolic 
Introduction
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flexibility [71]. Change in workload of the 
heart may lead to insulin resistance [77]. 
However, maneuvers to sustain myocar-
dial glucose oxidation and/or to prevent 
high fatty acid oxidation at least in obesity 
should be evaluated with great caution as a 
very recent published study on transgenic 
mice with cardiac-specific over-expression 
of the insulin-dependent glucose trans-
porter GLUT-1 demonstrated that chronic 
increases in myocardial glucose uptake 
and oxidation reduce the metabolic flex-
ibility and render the heart susceptible to 
contractile dysfunction [78].
Diabetes and ischemic heart 
disease
In diabetic patients over the age of 65 years, 
68% of deaths are from CHD and 16% are 
from stroke [79]. Insulin resistance, a car-
dinal feature of T2DM, is associated with 
a cluster of metabolic and biochemical ab-
normalities, including hyperglycemia, hy-
pertension, atherogenic dyslipidemia, in-
flammation, endothelial dysfunction, and 
impaired fibrinolysis [12, 63, 80-83]. Each 
of these abnormalities promotes the de-
velopment of atherosclerosis and clinical 
CVD. Longitudinal epidemiologic studies 
report a similar incidence of cardiovascu-
lar and all-cause mortality between sub-
jects who have diabetes without evidence 
of prior CHD and subjects who have CHD 
without prior diabetes [4, 84]. Notwith-
standing the growing incidence of T2DM 
in young adults and adolescents requires 
that any claims about diabetes as a CHD 
risk equivalent should be qualified by the 
age of the affected individual [81].
Diabetes and congestive heart 
failure
Despite improvements of treating CHF, 
mortality and hospitalization rates in dia-
betic patients with CHF remain high. The 
increased incidence of CHF in diabetic 
subjects remains high, despite controlling 
for confounders such as hypertension or 
CHD [85]. This might be caused by the 
direct effect of hyperglycemia on cardiac 
structure and function [86]. This feature 
is often called diabetic cardiomyopa-
thy. Recently it has been confirmed that 
a large proportion of patients presenting 
with the clinical syndrome of heart fail-
ure have a normal EF [87]. Among these 
patients, diastolic dysfunction is believed 
to be common [88]. A large proportion of 
the diabetic patients suffers from diasto-
lic dysfunction [89]. Approximately half 
of patients with overt CHF have diastolic 
dysfunction without reduced EF [89]. In a 
community based study of the prevalence 
of diastolic dysfunction Redfield et al. 
found that the frequency of CHF increased 
dramatically with increasing severity of di-
astolic dysfunction. However, even severe 
diastolic dysfunction is often subclinical 
with no recognized CHF diagnosis [89]. 
Moreover, there seems to be an inverse as-
sociation between the degree of metabolic 
control and signs of early diastolic dys-
function [88].
In heart failure, myocardial glucose 
uptake is compromised independent of 
etiology. This phenomenon is associated 
with cellular deficits of insulin signaling. 
Insulin resistance in heart failure can be 
detrimental, because transcriptional shifts 
in metabolic gene expression favor glucose 
over fat as a substrate (figure 3) for high-
energy phosphate production [90]. There 
are several lines of evidence that insulin 
resistance is associated with CHF [91, 92]. 
In a prospective community based study 
of elderly men, with a follow-up time of 
8.9 years,  Ingelsson et al. found that in-
sulin resistance predicted CHF incidence 
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independently of established risk factors 
such as diabetes [93].
The cardiotoxic triad of CHD, hyper-
tension/ventricular hypertrophy, and 
diabetic cardiomyopathy also leads to de-
creased ventricular function in chronic 
and acute situations [68]. Diabetes changes 
the myocardial extracellular matrix, which 
is evident from elevated interstitial and 
perivascular fibrosis, increased expression 
of collagen type I, and down regulation of 
collagen-degrading matrix metallopro-
teases [94]. These pathologic mechanisms 
are mediated by hyperglycemia, oxidative 
stress, and elevated aldosterone and angi-
otensin II levels [94].
Endothelial dysfunction predicts car-
diovascular mortality, correlates with the 
functional capacity of chronic CHF pa-
tients and plays a central role in the patho-
physiology of CHF, T2DM, hypertension 
Figure 3. Metabolic changes in the decompensated heart, and associations between 
insulin resistance, congestive heart failure and glucose-fat oxidation. 
When the heart is acutely stressed, it is able to switch from fat to carbohydrate as fuel for 
oxidative energy production. If the heart is exposed to changes in ventricular pressures it 
reactivates its fetal gene program. Reactivation of these fetal genes includes a switch from fat 
to glucose oxidation, which in the end might lead to increased insulin resistance. Change in 
workload of the heart results in a loss of insulin sensitivity.
Glucose            Fat
Myocardial
glucose uptake
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and chronic renal failure [95, 96]. The 
important messenger molecule NO exerts 
favorable effects on left ventricular diasto-
lic distensibility. Low myocardial NO bio-
availability has been demonstrated to re-
duce LV preload reserve in CHF patients 
[97]. Hyperglycemia induces oxidative 
stress via several mechanisms, which in-
clude glucose auto-oxidation, formation of 
advanced glycation end products (AGE), 
activation of the polyol pathway, and in-
creased levels of free fatty acids (FFA) [98]. 
eNOS is one  prominent vascular source 
of NO. In oxidative environments, pau-
city of tetrahydrobiopterin induces eNOS 
uncoupling, which leads to production of 
superoxide instead of NO, thereby ampli-
fying oxidative stress and endothelial dys-
function [86]. Evidence for uncoupling of 
eNOS has been obtained in patients with 
diabetes, hypertension, and hypercholes-
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terolemia [99].
Prevention of diabetic cardio-
vascular complications
A growing body of evidence suggests 
that diabetes can be prevented by lifestyle 
changes, such as an increase in physical ac-
tivity and lowered consumption of fat, car-
bohydrates and an increase in fiber intake 
[18]. Increasing participation in vigorous 
and non-vigorous exercise has been cor-
related with improved insulin sensitivity 
in subjects with normal glucose tolerance, 
IGT, and early T2DM [100]. Likewise, ex-
ercise is associated with reduced total cho-
lesterol levels and increased low-density 
lipoprotein cholesterol particle size, which 
are biomarkers for cardiovascular events 
[101]. Disappointingly, there is little evi-
dence to support a clear benefit of lifestyle 
interventions alone on cardiovascular 
morbidity or mortality in patients with 
T2DM or prediabetes [102]. 
The landmark study exploring antihy-
perglycemic treatment effectiveness on 
CVD complications in (newly diagnosed) 
T2DM is still the UKPDS [22, 51, 103, 
104]. In this study, intensive antihyperg-
lycemic treatment with sulfonylureas and 
insulin did not significantly reduce the risk 
for CVD, whereas metformin – as mono-
therapy - did so in a subgroup analysis of 
obese subjects [103]. However, the most 
striking long-term effect of lowering blood 
glucose appeared during the open post-
study observation period [51]. It is worth 
mentioning that the effectiveness of treat-
ing T2DM was more marked in reducing 
cerebrovascular and peripheral vascular 
disease but only of borderline significance 
for CHD. 
The studies that so far report the most 
successful results of preventing CVD in 
T2DM adopted a multifactorial strategy; 
in STENO 1 and 2, intensive intervention 
with multiple drug combinations and be-
havior modification had sustained benefi-
cial effects with respect to vascular com-
plications and on rates of death from any 
cause and from cardiovascular causes [20, 
21]. In fact, the number needed to treat 
for preventing one cardiovascular event in 
this study was as low as 3.4!
In 2008, a triad of randomized studies, 
Action to Control CardiOvascular Risk in 
Diabetes (ACCORD), Veterans Affairs Dia-
betes Trial (VADT) and Action in Diabetes 
and Vascular Disease: Preterax and Diami-
cron Modified Release Controlled Evalua-
tion (ADVANCE), in total some 23,000 
T2DM patients, have reported conflicting 
results on macrovascular endpoints in the 
context of various blood glucose-lowering 
regimes [21, 24, 105]. In the ACCORD 
trial, the intensive treatment arm surpris-
ingly had to be prematurely stopped after 
3.5 years due to increased mortality [23]. 
In contrast, the ADVANCE-trial reported 
a 10% reduction in a combined micro- and 
macrovascular endpoint, primarily as a 
consequence of a 21% relative reduction in 
nephropathy, but intensive treatment did 
not yield any significant reduction of mac-
rovascular events [24]. In the VADT trial, 
meticulous glucose control had no signifi-
cant effect on incident major cardiovascu-
lar events, death, or microvascular compli-
cations with the exception of progression 
of albuminuria [105]. In summary, trials 
evaluating patients with shorter duration 
of T2DM and a milder disease,  i.e. the 
UKPD [22, 51, 103,104] seem to show 
more benefit of intensive glucose control 
compared to patients with more severe 
disease and longer diabetes duration, i.e. 
ACCORD, ADVANCE and VADT [23, 24, 
105]. Interestingly there is evidence that 
some antidiabetic drugs may exert benefi-
cial cardiovascular effects independently 
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of their antihyperglycemic action. I will 
briefly discuss evidence for such effects 
below.
Anti-diabetic drugs with cardio-
vascular effects
Metformin
The biguanide drug metformin has been 
used in the treatment of T2DM almost for 
half a century and is recommended as first 
line treatment for T2DM, along with diet 
and exercise. Metformin exerts its antihy-
perglycemic effects primarily by decreas-
ing hepatic glucose output through acti-
vation of AMP-activated protein kinase 
(AMPK) [106, 107], and by increasing glu-
cose disposal in skeletal muscle [108] with 
a minimal risk of hypoglycemia. Also, it is 
increasingly clear that metformin contrib-
utes to weight gain limiting effects [109]. 
Some investigators suggest that metformin 
ameliorates endothelial function inde-
pendently of glycemia [110, 111]. 
In the UKPDS [103], metformin as 
monotherapy, but not in combination with 
sulfonylurea (SU), was associated with a 
decrease in macrovascular morbidity that 
appeared to be independent of glycemia. 
There is also some epidemiologic infer-
ence that metformin might be superior to 
sulfonylurea in terms of decreasing cardi-
ovascular mortality, as the drug in a retro-
spective cohort study was associated with 
lower mortality and morbidity in patients 
with T2DM and heart failure compared to 
sulfonylurea [112, 113].  
Sulfonylureas
Although there are studies indicating pos-
sible negative effects on vascular function 
by glibenclamide [114], there are also a 
few studies indicating that certain other 
SUs may improve endothelial function. 
Gliclazide protects human umbilical vein 
endothelial cells (HUVECs) from glucoa-
poptosis through anti-oxidative effects 
[115]. Also, glimepiride has been shown 
to influence endothelial cell function in 
a potentially positive way, inasmuch as it 
induces NO release from HCAECs by ac-
tivating the PI3K/Akt pathway [116] and 
promoting eNOS phosphorylation [117]. 
A small prospective study, aimed to inves-
tigate the progression of carotis intima- 
media thickness (cIMT) in T2DM, showed 
that cIMT increased less in the gliclazide-
treated group than in the glibenclamide 
group [118]. 
In the UKPDS, there were no differ-
ences in mortality and morbidity between 
groups treated with glibenclamide, insulin 
and chlorpropamide, respectively [22].
 In a retrospective cohort study, con-
sisting of 20,450 T2DM patients, McAl-
ister and coworkers found that users of 
high-dose sulfonylureas were more prone 
to develop incident CHF than users of 
high-dose metformin [119].
Thiazolidinediones
TZDs bind to the γ subtype of the per-
oxisome proliferator-activated receptors 
(PPARs). This leads to modulation of in-
sulin sensitivity and glucose homeostasis 
concomitant with a lowering of plasma 
FFAs [120, 121]. TZDs enhance NO bio-
availability in endothelial cells, including 
activation of eNOS [122, 123]. Direct ef-
fects of TZDs on vascular smooth mus-
cle cells have also been observed [124]. 
Recently, it was demonstrated that the 
TZD pioglitazone improves coronary en-
dothelial function in non-diabetic patients 
with CHD [125], and their progression of 
coronary atherosclerosis compared with 
glimepiride [126]. These data support the 
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view that TZDs’ beneficial effects on the 
endothelium might, at least in part, be in-
dependent of changes in glycemia. In the 
prospective pioglitazone clinical trial in 
macrovascular events (PROactive) study 
[127], there was a non-significant trend 
towards a relative risk reduction of the 
composite primary endpoint for pioglita-
zone-treated patients. More importantly, 
there was a significant reduction in the 
secondary endpoint of all cause mortality, 
MI or stroke. There was also a significantly 
increased number of edema and heart fail-
ure cases in the pioglitazone-treated group 
[127]. Peripheral edema is a well known 
side effect from TZD treatment; it is a dose-
dependent phenomenon and occurs early, 
up to 6 months after commencement of a 
TZD [128, 129]. In addition, pulmonary 
edema and CHF can occur from weeks to 
years after initiation of TZDs [130]. The 
mechanism of TZD induced edema is not 
fully understood but the kidney has been 
shown to differentially express all three 
PPAR subtypes. Lower levels of lithium 
clearance, which indirectly measures re-
nal proximal sodium absorption, has been 
shown during administration of piogli-
tazone. Taken together, this suggests an 
increased reabsorption of sodium in the 
proximal tubules due to PPAR stimulation 
[131]. 
In a meta-analysis, data from 42 trials 
were analyzed, concerning the cardiovas-
cular safety of rosiglitazone [132]. In the 
rosiglitazone group, as compared to the 
control group, the odds ratio for MI was 
1.43 and the odds ratio for death from car-
diovascular causes was 1.64. The conclu-
sion drawn was that rosiglitazone is asso-
ciated with a significant increase in the risk 
of MI, with an increased the risk of death 
from CVD. As a consequence of this and 
of other recently published meta-analyses 
[133, 134] the European medicines agency 
decided in September 2010 temporarily to 
recommend suspension of rosiglitazone–
containing drugs. 
Insulin
Human endothelial cells express the insu-
lin receptor [135]. It has become increas-
ingly clear that insulin may exert vasoac-
tive effects, insofar as it can enhance blood 
flow and vasodilatation in a NO-depend-
ent fashion upon i.v. administration [136-
138]. Insulin enhances blood flow through 
different types of vessels, e.g. capillary and 
resistance vessels [139].
There is compelling evidence that in-
sulin directly enhances the production 
of NO by the endothelium via signaling 
pathways involving PI3K activation, which 
in turn stimulates eNOS phosphorylation 
[140-142]. In addition to activation of the 
PI3K-eNOS pathways, insulin also appears 
to influence the endothelium via MAPK-
dependent pathways that promote smooth 
muscle cell migration and ET-1 produc-
tion [143]. 
In the UKPDS, intensive glucose con-
trol with insulin or SU significantly re-
duced microvascular complications [22]. 
For MI, the relative risk reduction was 
borderline significant, but neither insulin 
nor SU did, despite weight gain and hy-
perinsulinemia, increase the risk of CVD 
events. The recently published UKPDS 80 
report demonstrated a continued reduc-
tion of microvascular risk and an emer-
gent risk reduction for MI, despite an early 
loss of glycemic differences [51]. 
Interestingly there are data suggesting 
that infusion of glucose-insulin-potassium 
(GIK) might induce acute effects on the 
heart and left ventricular performance. 
Studies investigating hemodynamic effects 
of GIK shows that GIK infusion results in 
increased cardiac output, less need for ino-
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tropic agents, and reduction in duration of 
intensive care unit stay in patients directly 
after coronary artery bypass grafting, both 
in nondiabetic and diabetic patients [144-
146]. Smaller experimental studies per-
forming echocardiography during GIK 
infusion in several types of patients report 
an enhancement in segmental wall mo-
tion in dyssynergic segments. [147, 148]. 
Klein and coworkers demonstrated that 
GIK improves regional left ventricular 
function and allows the detection of myo-
cardial viability to a similar extent as low-
dose dobutamine in patients shortly after 
infarction [149]. In the DIGAMI 1 study, 
insulin-glucose infusion followed by in-
tensive subcutaneous insulin therapy in 
diabetic patients with acute MI was found 
to improve long term survival; overall 
mortality was reduced by 11% (absolute 
risk reduction) [150]. These differences 
were sustained for more than three years. 
The DIGAMI 2 study was designed to in-
vestigate whether this substantial reduc-
tion in mortality was due to glycemia or 
insulin effects per se. However, the study 
failed to show any differences between the 
intervention groups, in terms of impact on 
long term and short term mortality [151]. 
Regrettably, this study must be considered 
inconclusive as the three groups (group 1, 
acute insulin-glucose infusion followed by 
insulin-based long-term glucose control; 
group 2, insulin-glucose infusion followed 
by standard glucose control; and group 3, 
routine metabolic management according 
to local practice) did not differ in HbA1c 
levels. The epidemiological analysis from 
the DIGAMI 2 study supports the concept 
that meticulous glucose control, rather 
than insulin treatment per se, is the major 
determinant of improved survival in sub-
jects with hyperglycemia and MI [151]. 
However, it was recently suggested by the 
same investigators that insulin might be 
harmful unless normoglycemia is achieved 
[152].
Despite a large body of data from clini-
cal trials, the issue remains unsettled as to 
whether insulin treatment in patients with 
diabetes and recent MI can reduce the risk 
of recurrent CVD and death.
Incretins
After meal ingestion, multiple gastrointes-
tinal hormones are secreted. These hor-
mones are involved in the regulation of gut 
motility, secretion of pancreatic enzymes, 
gall bladder contraction and nutrient ab-
sorption. The observation that the insulin 
secretion after orally ingested glucose ex-
ceeded the insulin secretion levels elicited 
by an equal amount of i.v. administered 
glucose led to the conclusion that there 
must be endogenous factors in the gut 
besides the glucose load per se promot-
ing this enhanced insulin response. These 
putative factors were named incretins and 
the effect was termed “the incretin effect” 
[153]. Two major mediators were subse-
quently identified: Glucose-dependent 
insulinotropic polypeptide (GIP) and 
glucagon-like peptide-1. GLP-1 exists in 
two circulating equipotent forms: (GLP-1)
(7-37) and GLP-1 (7-36) amide [154]. The 
first study of GLP-1 (7-36) amide (herein 
referred to as GLP-1) was published al-
most 3 decades ago with the cloning of a 
glucagon-related peptide from the prepro-
glucagon gene in anglerfish [155]. GLP-1 
is secreted mainly from the L-cells in the 
small bowel and colon and is a product of 
the partial proteolysis of preproglucagon. 
GLP-1 lowers blood glucose by augmen-
tation of insulin secretion and inhibiting 
glucagon secretion [156-159], but it also 
diminishes bowel motility and promotes 
the feeling of satiety [160-163]. GLP-1 is 
rapidly degraded by the ubiquitous en-
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zyme dipeptidyl peptidase 4 (DPP-4) [160-
163]. The biological half-life of GLP-1 in 
plasma is therefore very short, i.e. 1-2 min. 
The degradation metabolite GLP-1 (9-36) 
amide lowers glucose to a much lesser 
extent compared to native GLP-1, effects 
that seem to be independent of insulin and 
glucagon secretion and the rate of gastric 
emptying [164]. The different GLP-1 iso-
forms are listed in table 2.
GLP-1 receptors
The actions induced by GIP and GLP-1 are 
believed to be mediated through G-protein 
coupled receptors. The GLP-1 receptor 
(GLP-1R) was first detected by transient 
transfection of a cDNA library prepared 
from rat pancreatic islets into COS cells 
Figure 4. GLP-1 actions in peripheral tissues.  
GLP-1 acts directly on the endocrine pancreas, heart, stomach, and brain, whereas actions on 
liver and muscle are indirect. Reprinted from Cell Metabolism, volume 3, issue 3, Drucker DJ, 
The biology of incretin hormones, page 154, © 2006, with permission from Elsevier.
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and subsequent characterization of the 
binding of radio-labeled GLP-1 to these 
cells [165]. Human pancreatic GLP-1R is 
approximately 90% homologous with the 
corresponding rat protein [166, 167].
Expression of GLP-1R has been de-
tected in a wide range of tissues, including 
the pancreatic islets, lungs, kidneys, heart, 
(7-36)amide
(7-37)
(1-36)amide
(1-37)
(9-36)amide
(9-37)
Table 2. GLP-1 isoforms
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vessels, stomach, intestines, pituitary, skin 
and several regions of the CNS (figure 4) 
[168]. Although physiological actions of 
GLP-1 on the liver, skeletal muscle and 
fat cells have been reported, evidence for 
the expression of GLP-1R in these tissues 
is ambiguous. Ligand-binding analyses 
reveal that the Kd for binding of GLP-1 to 
its receptor is approximately 1 nM [169], 
and that exenatide displays a similar af-
finity [170, 171]. Exendin (9-39), an NH2-
terminally truncated form of exenatide, 
also binds to the GLP-1R and is a strong 
antagonist of the receptor-dependent ac-
tions of GLP-1 and exenatide [171].
Stimulation of pancreatic β-cells by 
GLP-1 or exenatide, believed to be medi-
ated via adenylate cyclase and the cAMP/
PKA pathways, potentiates glucose-in-
duced closure of ATP-sensitive K+ chan-
nels, thereby generating cellular depolari-
zation, activation of voltage-dependent 
Ca2+ channels (VDCCs) and a consequent 
influx of Ca2+ that sets secretion of insu-
lin in motion [172]. Agonists of GLP-1R 
also evoke several other responses in the 
rodent pancreas, including enhanced pro-
liferation and inhibition of apoptosis of 
β-cells [173, 174].
Antihyperglycemic effects of 
GLP-1 
GLP-1 exerts a transient rise in insulin se-
cretion and suppression of glucagon, both 
of which are glucose-dependent [156, 157, 
160-163]. This dual mechanism of glucose 
dependent hormone secretion minimizes 
the risk of GLP-1-induced hypoglycemia, 
in contrast to other insulin secretagogues 
such as SU and glinides [175]. Several 
studies have shown that short-term in-
fusions, i.e. (i.v. and s.c.) of GLP-1 lower 
blood glucose levels in both type 1 and 
type 2 diabetic subjects [156, 157, 176]. 
In a 6-week study in T2DM patients, 
GLP-1 infusion resulted in augmentation 
of insulin secretion, reduction of HbA1c 
(1.2%), a weight loss of 1.9 kg and im-
provements of insulin sensitivity [177]. In 
contrast to GLP-1, GIP seems to lose its 
insulinotropic effects in diabetic subjects 
possibly through receptor down-regula-
tion or desensitization [158]. The ability of 
GIP to stimulate second phase insulin se-
cretion is absent in T2DM, although a first 
phase response is present [178].
Incretin agonists
Due to the very short half-life of GLP-1, 
caused by DPP-4 degradation, GLP-1 
agonists resistant to this degradation and 
DPP-4 inhibitors have been developed. 
The first known GLP-1R agonist, resist-
ent to DPP-4 degradation, that came to be 
used for clinical purposes was originally 
found in the saliva of the lizard Heloder-
ma suspectum. This peptide was named 
exendin-4 (exenatide is synthetic exend-
in-4). It shares a 53% amino acid sequence 
homology with that of native GLP-1 (fig-
ure 5) giving it a circulating plasma half-
life of 60-90 min [179]. In clinical trials 
with T2DM patients, addition of exenatide 
on top of metformin, SU or both reduces 
HbA1c with 0.8-1.0% and gives a weight 
reduction of 0.9- 2.5 kg in overweight pa-
tients [180-182].
Liraglutide, almost a GLP-1 “twin” with 
~ 97% homology to the native peptide, 
contains an arginine34lysine substitution, 
a glutamate substitution and a FFA ad-
dition to lysine. It also binds to albumin, 
resulting in a plasma half-life of 10-14 
hours after s.c. injection [154, 183]. Li-
raglutide can be administered once daily 
and reduces both fasting and postpran-
dial glycemia. The Liraglutide Effect and 
Action in Diabetes (LEAD) program was 
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Figure 5. Structure of GLP-1 (7-36), GLP-1R agonists liraglutide and exenatide. 
Reprinted from The Lancet: Drucker DJ, The incretin system: glucagon-like peptide-1 receptor 
agonists and dipeptidyl peptidase-4 inhibitors in type 2 Diabetes, page 1697, © 2006, with 
permission from Elsevier.
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designed to compare the efficacy and tol-
erability of once-daily liraglutide alone 
or in combination with other commonly 
used oral agents, for T2DM [184-188]. 
In all these studies  (except for LEAD II), 
reductions of HbA1c of up to 1.6 % were 
observed with liraglutide as monotherapy 
or in combination with oral antidiabetes 
agents (OAD) [184-188]. Liraglutide also 
improved surrogate measures of β-cell 
function, reduced systolic blood pressure 
up to 6.7 mm Hg and was associated with 
weight loss up to 3.2 kg [184-189].
DPP-4 inhibitors
The inhibitors of DPP-4 in current clinical 
use are low-molecular weight compounds 
with good oral bioavailability, in contrast 
to peptides, i.e. GLP-1 analogues. DPP-4 
knock-out mice have increased levels of 
intact GLP-1 with concomitant increased 
insulin and decreased glucose levels after 
OGTT [190]. The first DPP-4 inhibitor ap-
proved for clinical purposes was sitaglip-
tin. Vildagliptin and saxagliptin are other 
DPP-4 inhibitors in clinical use, and sever-
al others, e.g. linagliptin and alogliptin, are 
in phase II-III clinical trials. These agents 
are highly selective for DPP-4 inhibition, 
thus not appreciably affecting DPP-8 and 
DPP-9. In contrast to GLP-1 analogues, 
DPP-4 inhibitors are not associated with 
inhibited gastric emptying, nausea or 
weight loss, probably due to the relatively 
modest incretin effect (postprandial GLP-1 
levels 15-25 pmol/l) [154]. The plasma 
half-life of sitagliptin is 8-14 h, resulting in 
an 80% inhibition of plasma DPP-4 activ-
ity 24 h after oral administration.
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GLP-1 secretion
The plasma levels of GLP-1 rise after in-
gestion of glucose, sucrose or fat [191]. 
Normally, basal levels of the peptide are 
approximately 5 pmol/l and they rise to 
15- 40 pmol/l one hour after food inges-
tion. In a study by Laakso et al. differences 
in GLP-1 concentrations between NGT, 
IGT and IFG subjects could be seen from 
60 to 120 min post-glucose challenge. In 
this study, NGT subjects had significantly 
higher post challenge GLP-1 levels com-
pared to IGT and IFG subjects. However, a 
recent review has challenged the view that 
glucose intolerant individuals have GLP-1 
deficiency [192].
GLP-1 and insulin resistance
After food intake, the rate of insulin se-
cretion depends not only on the degree of 
glycemia, but also on the insulinotropic 
effects of the incretin hormones GLP-1 
and GIP, and many other types of input 
[193]. There are to date conflicting data as 
to whether GLP-1 acutely affects insulin 
sensitivity or not. In one study on subjects 
with stable CHD and T2DM, infusion with 
GLP-1 did not affect whole body glucose 
uptake [194]. A study in non-diabetic men 
showed that the GLP-1 and GIP responses 
to a mixed meal correlated significantly 
with the degree of insulin resistance [195]. 
Recently, a study randomizing T2DM pa-
tients to either glibenclamide or exenatide 
(5 µg bid) showed - in contrast to the other 
studies reported in literature - positive ef-
fects of exenatide on insulin resistance and 
inflammatory state parameters like resis-
tin, retinol binding protein-4, and hs-CRP 
[196]. In this study insulin resistance was 
measured by HOMA-IR, which decreased 
significantly in response to exenatide com-
pared to glibenclamide treatment. How-
ever, the improvement of insulin sensitiv-
ity and inflammatory biomarkers in the 
exenatide arm might have been caused 
by the decrease in body weight (6.3 kg) or 
BMI (2.2 kg/m2) in these subjects.
Incretin effects on the  vascula-
ture and heart 
In addition to the multitude of well-char-
acterized actions of GLP-1 on glycemic 
endpoints, expression of GLP-1R has been 
detected in the vasculature [194, 197, 198] 
and a growing body of evidence has accu-
mulated that implicate incretin action in 
the vasculature and the human heart.
Preclinical observations 
Vasculature
Early experiments by Barragan showed 
that i.v. [199, 200] and intracerebroven-
tricular administration of GLP-1 and ex-
enatide to rodents elevates both blood 
pressure and heart rate [201-203]. In one 
study vagotomy was found to prevent the 
blood pressure and heart rate elevating ef-
fects of intracerebroventricularly adminis-
tered GLP-1, as did intracerebroventricular 
administration of the GLP-1R antagonist 
exendin 9-39 [201]. These findings sug-
gest that GLP-1 exerts cardiovascular ef-
fects  through the central nervous system, 
initially by parasympathetic transmission. 
Furthermore, it has been shown that GLP-1 
can pass through the blood-brain barrier 
by simple diffusion [204]. There are also 
studies that reveal dose-dependent relax-
ant effects of GLP-1 on vascular rings iso-
lated from rodents ex vivo [205, 206]. The 
GLP-1 analogue liraglutide has recently 
been shown to exert an anti-inflammatory 
effect on vascular endothelial cells by in-
creasing NO production and suppressing 
NF-κB activation, probably partly caused 
by AMPK activation [207]. Investigations 
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with chronic GLP-1 treatment of Dahl 
rats fed a high-salt diet partially protected 
these animals from endothelial dysfunc-
tion; the vasodilator response of the GLP-
1-treated rats to ACh was almost twice as 
great as that seen in the animals receiving 
vehicle alone [208]. 
The GLP-1 analogue exenatide also in-
duces Fos-like immunoreactivity (Fos-IR) 
in neurons in the paraventricular nucleus 
of the hypothalamus  [203, 209]. Interest-
ingly it is proposed that increased activity 
of these neurons contributes to increases in 
blood pressure and  heart rate [203]. These 
observations suggest that the cardiovascu-
lar actions of exenatide involve integration 
of both indirect neural and direct cardiac 
effects, thereby linking signaling through 
the GLP-1R to activation of the sympa-
thetic nervous system. 
It was recently demonstrated that 
brain GLP-1R signaling simultaneously 
controls arterial blood flow and glucose 
utilization, and hypothalamic NOS activ-
ity in a glucose-dependent manner [210].
However, findings concerning the pos-
sible non-adrenergic [199] vs. adrener-
gic effects [203] of GLP-1 appear to be 
ambiguous. Exenatide causes substantial 
β-adrenoceptor-mediated hindquarter va-
sodilatation and tachycardia through sym-
pathoadrenal activation, and it was recent-
ly proposed that this substance may cause 
opposing hemodynamic effects, i.e. me-
senteric vasoconstriction and hindquarter 
vasodilatation by activating both β-and 
α-adrenoceptors [211]. Furthermore, ad-
ministration of exenatide or GLP-1 to rats 
with streptozotocin/nicotinamide-induced 
diabetes nearly normalized their vascular 
tone [212]. The restoration of endothelial 
function in these two models appeared to 
be secondary to the improvement in glyc-
emic control, rather than direct endothe-
lial effects of exenatide or GLP-1. 
Heart
Interestingly, some recent papers have re-
ported cardiac actions of the endogenous 
metabolite of GLP-1, i.e. GLP-1 (9-36) 
amide, independent of the known GLP-
1R [197]. Furthermore several studies, in 
various animal models, have shown that 
GLP-1 or GLP-1 analogs may limit myo-
cardial infarct size [197, 213-219]. Moreo-
ver exenatide has been shown to reduce 
intimal hyperplasia in Zucker fatty rats 
[220]. Very recently a group demonstrated 
that isolated mouse heart rapidly converts 
GLP-1 to GLP-1 (9-36) amide [221]. In 
this study it was shown that the metabo-
lite GLP-1 (9-36) amide exerts cardiopro-
tective actions in the mouse heart ex vivo, 
limiting infarct size after ischemia-reper-
fusion injury. Additionally, GLP-1 (9-36) 
amide, but not exenatide, also promoted 
cell survival in isolated cardiomyocytes 
from GLP-1R-/- mice and in human coro-
nary artery endothelial cells (HCAEC) 
[221]. The authors concluded that this 
supports the existence of an alternative 
receptor for GLP-1 (9-36) amide. Anoth-
er study shed some light on the question 
whether increasing circulating GLP-1 lev-
els by DPP-4 inhibition can exert effects 
direct on the heart. In this study Ye et al. 
showed that pretreatment with sitagliptin 
could limit myocardial infarct size, along 
with increased myocardial levels of cAMP 
and PKA activity in mice. The myocardial 
infarct size limiting effects of sitagliptin 
was completely blocked by a PKA inhibi-
tor, suggesting that this effect is PKA de-
pendent [222]. 
In animal in vivo studies, exploring the 
effects of GLP-1 on left ventricular func-
tion, GLP-1 has been shown to ameliorate 
left ventricular dysfunction in dogs with 
pacing-induced dilated cardiomyopathy 
[90] and to limit myocardial stunning in 
conscious canines [223]. A recently pub-
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lished study showed that GLP-1 infusion 
in conscious dogs with pacing-induced 
dilated cardiomyopathy stimulates myo-
cardial glucose uptake through a p38α 
MAP kinase-mediated and NO-depend-
ent mechanism [224]. In this study, indica-
tions that the improvement in LV function 
was not mediated by β-adrenergic stimula-
tion were found [224], in contrast to other 
studies with exenatide and GLP-1 [211]. 
Interestingly there are several studies dem-
onstrating that central GLP-1R stimula-
tion increases heart rate, in both anesthe-
tized and freely moving rodents [199, 203, 
210, 225].  Finally, there is some evidence 
that the the positive chronotropic effects 
of central GLP-1 receptor stimulation may 
result from changes in parasympathetic 
activity [199, 203, 210, 225, 226]. 
Clinical observations
Vasculature
In patients, both the systolic and diastolic 
blood pressure are reduced following 82 
weeks of treatment with exenatide, prob-
ably as a consequence of improvements in 
blood levels of glucose and lipids and a re-
duction in body weight [228]. A recently 
published metaanalysis explored the ef-
fects of exenatide vs. placebo or insulin 
on blood pressure in pooled data from 
six trials including 2,171 subjects studied 
for at least 6 months. The authors in this 
analysis concluded that overall 6 months 
of exenatide treatment was associated with 
a significantly greater reduction in systolic 
BP (SBP) compared with placebo (differ-
ence of -2.8 mm Hg) or insulin (differ-
ence of -3.7 mm Hg). There was a weak, 
albeit statistically significant, correlation 
between weight loss and the reduction of 
SBP [229]. One study with shorter follow-
up time failed to detect significant reduc-
tions of SBP in exenatide-treated patients 
[230]. Vilsboll et al. reported that 14 weeks 
of treatment with the long-acting GLP-1 
analog liraglutide improved glycemic con-
trol and lowered body weight, while sig-
nificantly decreasing SBP [231]. Interest-
ingly, the reduction in SBP occurred prior 
to the effect on body weight, indicating 
direct effects of liraglutide on SBP. Moreo-
ver, GLP-1 increases sympathetic vasocon-
strictor neural activity but does not appear 
to affect cardiac sympathetic or parasym-
pathetic activity in healthy humans [227].
Acute infusion of GLP-1 into T2DM 
patients with stable CHD ameliorates their 
endothelial dysfunction [194]. Short-time 
infusion of GLP-1 into healthy human 
subjects increased both normal and ACh-
induced vasodilatation independent of 
alterations in glycemia and insulin levels 
and these effects were abolished by glib-
enclamide, an effect suggested to be medi-
ated via KATP channels [232].
In a study investigating changes in en-
dothelial function measured by peripheral 
arterial tonometry after a high-fat meal, 
Koska et al found that exenatide amelio-
rates postprandial endothelial dysfunc-
tion and that changes in triglycerides con-
centrations explained 64 % of this effect 
[233].   
Heart 
Nikolaidis et al. published the first study 
that showed that GLP-1 infusion can im-
prove left ventricular function in patients 
after successful reperfusion following an 
MI [234]. In 2006, Sokos et al. found that a 
5-week infusion with GLP-1, compared to 
standard therapy, improved left ventricular 
function and quality of life in patients with 
New York Heart Association class III/IV 
heart failure [235]. Interestingly, benefits 
were seen in both diabetic and non-dia-
betic patients in these two studies. Very re-
cently it was demonstrated that inhibition 
of DPP-4 improved global and regional 
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wall LV function during dobutamine stress 
[236]. However, not all publications have 
shown cardiovascular beneficial effects of 
GLP-1 treatment; a study determining car-
diac index in non-diabetic patients could 
not detect any improvement of left ven-
tricular function after short-time infusion 
with GLP-1 [237].  
Exenatide treatment has been associ-
ated with improved cardiovascular risk 
biomarkers, e.g. high-sensitive CRP, en-
dothelin-1 levels and increased total adi-
ponectin concentrations, independently of 
changes in body composition[238]. Treat-
ment with liraglutide is known to associate 
with reduction of plasminogen activator 
-1 (PAI-1) and brain natriuretic peptide 
(BNP) but not significantly with high sen-
sitivity CRP (hs-CRP) levels [239].
Epidemiological observations  
There are to date very few epidemiologi-
cal studies exploring potential associations 
between GLP-1 and CVD.  In a Japanese 
study on individuals at high risk for CVD, a 
positive correlation between fasting GLP-1 
levels and accumulation of components of 
the metabolic syndrome was found [240].
Very recently, a retrospective analysis of 
the LifeLink database demonstrated a low-
er risk of CVD events in 39,275 exenatide-
treated subjects compared to 381,218 non-
exenatide treated diabetic subjects [241].
Ongoing studies
The scientific field exploring cardiovascu-
lar effects of GLP-1 and its analogs is now 
expanding very fast. This is illustrated by 
a PubMed search on GLP-1 and heart that 
showed 116 published original papers in 
April 2010, twice as many as published in 
January 2007. 
At present, several studies evaluat-
ing long-term cardiovascular effects of 
incretins are ongoing: The Exenatide 
Study of Cardiovascular Event Lowering 
Trial (EXSCEL), Sitagliptin Cardiova-
scular Outcome Study (TECOS) and Li-
raglutide Effect and Action in Diabetes: 
Evaluation of Cardiovascular Outcome 
Results - A Long Term Evaluation (LEAD-
ER) study are all randomized long - term 
studies that will investigate the impact of 
exenatide, sitagliptin and liraglutide on 
major cardiovascular outcomes.
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The specific aims were:
I.   To analyze whether GLP-1 plasma lev-
els may predict CHD incidence, and to 
investigate potential cross-sectional as-
sociations between GLP-1 plasma lev-
els, glucose abnormalities( i.e. diabetes 
and IGT) and insulin sensitivity.
II.  To analyze whether GLP-1 plasma lev-
els may predict CHF incidence, and 
to investigate potential cross-sectional 
associations between GLP-1 plasma 
levels and echocardiographic measures 
of left ventricular function. 
III. To investigate therapeutic effects of the 
GLP-1 mimetic exenatide on left ven-
tricular function and hemodynamic 
profile in T2DM patients with decom-
pensated heart failure. 
IV.   To investigate if exenatide can protect 
against lipid-induced endothelial dys-
function in rat vascular tissue ex vivo 
and to explore potential differences in 
vasoactivity between GLP-1 (7-36), 
GLP-1 (9-36) and exenatide.  
V.   To explore whether incretins influence 
proliferation of HCAECs in vitro, and 
to elucidate the molecular mecha-
nisms behind such effects.
Aims
The primary aim of this thesis was to investigate whether a group of peptides, incre-
tins, with antihyperglycemic properties exert any physiologic or pharmacologic role in 
the endothelium, vasculature and human heart.
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Translational research
Translational research by definition trans-
forms scientific discoveries arising from 
laboratory, clinical, and population studies 
into clinical applications to reduce disease 
incidence, morbidity, and mortality. This 
thesis could be referred to as the product of 
a translational research effort as it is based 
on five studies using completely different 
methods, ranging from epidemiological 
analyses in cohort studies to molecular 
cell biological analyses of intracellular sig-
nal transduction pathways controlling the 
proliferation of human coronary artery 
endothelial cells to address a common is-
sue:  do incretins  per se have an impact on 
the cardiovascular system? 
Patients and study protocols
Study I and II
Study population
These studies are based on the ULSAM 
(Uppsala Longitidinal Study of Adult 
Men) cohort (http://www.pubcare.uu.se/
ULSAM/). All men born in 1920 to 1924, 
who were residents of the municipality of 
Uppsala, Sweden, were invited to partici-
pate in a health examination survey carried 
out between April 1970 and October 1973, 
which aimed at identifying risk factors 
for CVD. Of the 2,841 men invited, 2,322 
participants (82%) participated in the in-
vestigation at age 50 [242]. The men were 
invited for reexamination at age 60, 70, 77 
and 82. The data has been completed with 
annual updates on mortality and in-hospi-
tal morbidity using national registers. The 
examination at age 70, which forms the 
baseline of the present study, was carried 
out between August 1991 and May 1995. 
Of the 1,681 available 70-year-old men 
1,221 (73%) attended. Out of these men, 
random plasma samples from 509 subjects 
were stored frozen at -70°C and analyzed 
for their GLP-1 concentrations in 2007. In 
study I (figure 6), 62 men were excluded 
due to prior MI or angina pectoris (ICD-9 
codes: 410–414, ICD-10 codes: I20–25) in 
the prospective analyses. In study II (fig-
ure 6), seven participants were excluded 
due to previous diagnosis of CHF and four 
due to a diagnosis of valvular disease in 
the hospital discharge register at baseline. 
In the cross-sectional part of study II, as-
sociations between echocardiographic 
measurements of left ventricular systolic 
and diastolic (i.e. E/A ratio) function and 
GLP-1 concentrations were investigated. 
This cross-sectional study consisted of 377 
out of 509 men, who had technically satis-
factory echocardiographic evaluations, i.e. 
acoustic window limitations, atrial fibril-
lation/flutter and valvular disease (n=132) 
were all excluded. Fifteen participants 
with EF <50% were excluded in an attempt 
to adjust for pseudo-normalization of the 
E/A ratio.
Outcome definitions
T2DM, IGT and NGT were defined ac-
cording to the WHO criteria from 1999 
[243], i.e. OGTT using 2-h post glucose 
load concentrations and/or use of OHAs.
Information concerning mortality and 
morbidity from incident disease was col-
lected from the official Swedish registries: 
Cause of death (CDR), Swedish cancer 
(SCR) and in-patient (IPR) registries held 
by The Center for Epidemiology, National 
Board of Health and Welfare in Sweden. In 
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study I the outcome CHD was defined us-
ing the registry data as death, as recorded 
in the CDR or for the first time hospital-
ized for CHD (ICD-9 codes 410-414, ICD-
10 codes I20-I25), as recorded in the IPR, 
(censor date December 31, 2006). In study 
II, heart failure was chosen as outcome. 
Consequently, ICD heart failure codes 
428 (ICD-9) and I50 (ICD-10) and hy-
pertensive heart disease with heart failure, 
I11.0 (ICD-10) were eligible. The medical 
records from the hospitalization were re-
viewed for adjudication by two physicians 
blinded to the baseline data, who classified 
the cases as definite, questionable, or mis-
coded [93]. After this validation, 40 defin-
itive cases of heart failure were included in 
the cohort. 
Study III
Study population
The study subjects were patients with 
T2DM hospitalized for heart failure at the 
Departments of Cardiology and Internal 
Medicine at Södersjukhuset, Stockholm. 
Twenty male patients aged 57-79 years 
with T2DM and worsened heart failure 
(NYHA class III-IV) were recruited for the 
study.
Protocol
This was a randomized, cross-over, dou-
ble-blinded study. The patients underwent 
i.v. infusions during two consecutive days 
with a) exenatide (0.12 pmol·kg-1·min-1) 
and b) saline for 6 hours separated by a 
washout period for 18 hours (figure 7). 
The order of the two sessions (a and b) 
was randomized. Hemodynamics; pulmo-
nary capillary wedge pressure (PCWP), 
right atrial  pressure (RAP), and pulmo-
nary arterial mean pressure (PAP) were 
monitored with a pulmonary artery cath-
eter (Swann-Ganz) and cardiac ouput 
(CO) was determined by thermodilution. 
Cardiac index (CI) was calculated from 
CO and body surface area (BSA). Mean 
arterial blood pressure (MAP) was deter-
mined by an intra-arterial catheter. Dur-
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Figure 6. Schematic overview of the Uppsala Longitudinal Study of Adult Men.
Study I and study II.
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ing the 6-hour infusions of placebo/ex-
enatide, all antihyperglycemic drugs were 
stopped and replaced with i.v. infusion of 
regular insulin (Actrapid®) to achieve nor-
moglycemia (4-6 mmol/l). During the in-
fusions, CO, PCWP, RAP, PAP and MAP 
were measured at baseline, 1 hour, 3 hours 
and 6 hours after start of infusions. Blood 
samples for analyses of insulin, C-peptide, 
glucagon, exenatide and NEFA concentra-
tions were drawn simultaneously as the he-
modynamic parameters were monitored. 
Laboratory studies- protocols
Study IV
Sixty-nine non-diabetic male Sprague–
Dawley rats (weight 250–350 g) were an-
esthetized with a mixture of fluanisonum 
and fentanylum (Hypnorm®, Janssen, 
Beerse, Belgium) and midazolam (Dor-
micum®, Hoffman-LaRoche, Basel, Swit-
zerland) (2.5, 0.08 and 1.25 mg/kg, respec-
tively, i.m.). The rats were then killed by 
excision of the heart. The contractile func-
tion of the vascular segments was tested 
by administration of phenylephrine. En-
dothelium–dependent and–independent 
relaxations were determined by adminis-
tration of acetylcholine (ACh) and sodium 
nitroprusside (SNP), respectively. After 
the end of the functional tests, artery rings 
were frozen and stored at -80°C pending 
immunoblotting analysis. For determina-
tion of cAMP contents, the thoracic aorta 
was removed, cleaned and cut into two 
sections. Each vessel segment was equili-
brated for 20 min in Krebs-Henseleit (KH) 
solution at 37°C and bubbled with 5% CO2 
in O2 to maintain a pH of 7.4, before in-
cubation. One vessel segment was then 
incubated for 15 min with GLP-1 (100 
nM) or exenatide (2.5 nM), respectively, 
and the other with an equivalent volume 
of the adenylate cyclase activator forskolin 
(10 μM) or its solvent DMSO (10 μM), the 
former serving as a positive control. Ves-
sels were then frozen and stored at -80°C 
for further analysis, i.e. phosphorylation 
of eNOS and expression of GLP-1R.
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Figure 7. Schematic overwiew of the study III protocol
Material and methods
33
Material and methods
Study V
Human coronary artery endothelial cells 
(HCAECs) (passage 4-13), isolated from 
normal human coronary arteries, pur-
chased from Clonetics (Lonza, Walk-
ersville, MD), were grown in complete 
EGM-2 MV medium supplemented with 
hydrocortisone, human epidermal growth 
factor (hEGF), 5% fetal bovine serum 
(FBS), vascular endothelial growth factor 
(VEGF), human fibroblast growth factor 
(hFGF)-B, R3-insulin-like growth factor 
(IGF)-1, ascorbic acid and gentamicin/
amphotericin-B at 37°C in a humidified 
(5% CO2, 95% air) atmosphere as rec-
ommended by the supplier. Confluent 
cell cultures were detached by trypsin-
2-[2-(Bis(carboxymethyl)amino)ethyl-
(carboxymethyl)amino]acetic acid (ED-
TA) and seeded onto tissue culture dishes 
for evaluation of [3H]thymidine incorpo-
ration rates, cell counting and Western 
blotting. 
To examine the effects of exenatide 
on cell viability, DNA synthesis, eNOS- 
and Akt phosphorylation, HCAECs were 
grown to 90% confluence, followed by an 
incubation overnight in serum-deficient 
EBM medium containing 0.5% FBS and 
2 mM L-glutamine. The eNOS inhibitor 
L-NAME (1 mM) or the PI3K inhibitor 
LY294002 (2 µM) were added 30 min prior 
to exenatide stimulation and continuously 
present as the incubation was continued 
for 48 h.
Biochemical analyses, clinical 
investigations and laboratory 
methods
Plasma glucose
Concentrations of plasma glucose were 
analyzed by the glucose dehydrogenase 
method (Gluc-DH, Merck, Darmstadt, 
Germany).
GLP-1 (Study I and II)
The plasma concentrations of GLP-1 were 
measured by radio-immunoassays after 
extraction of plasma with 70% ethanol 
(vol/vol, final concentration). Carboxy-
terminal GLP-1 immunoreactivity was 
determined using antiserum 89390. This 
antiserum has an absolute requirement 
for the intact amidated carboxy-terminus 
of GLP-1 (7-36) amide and cross-reacts 
less than 0.01% with carboxy-terminally 
truncated fragments and 89% with GLP-1 
(9-36) amide, the primary metabolite of 
DPP-4-mediated degradation. Sensitiv-
ity was below 5 pmol/l and the intra-assay 
coeffici ent of variation below 10% [191].
Immunoreactive insulin  
(Study I)
Serum immunoreactive insulin (IRI) con-
centrations were determined with the en-
zymatic immunological assay Enzymmun® 
Figure 6. Typical light microscopical ap-
pearance of semi-confluent HCAEC cul-
tures.
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(Boehringer Mannheim, Mannheim, Ger-
many, [ELISA]) performed in an ES300 
automatic analyzer (Boehringer Mannhe-
im, Mannheim, Germany) [244].
OGTT (Study I and II))
A 75 gram OGTT was performed and 
blood samples for plasma glucose were 
drawn immediately before and 120 min 
after the ingestion of glucose. Samples 
drawn immediately before and 60 min af-
ter ingestion of glucose were available for 
analysis of GLP-1. We calculated the dif-
ferences between plasma levels of GLP-1 
at 60 min after the OGTT (60GLP-1) and 
fasting plasma levels of GLP-1 (fGLP-1), 
creating the dynamic predicted variable 
ΔGLP-1 (60GLP-1 - fGLP-1 = ΔGLP-1).
Euglycemic insulin clamp 
(Study I and II)
An euglycemic insulin clamp was per-
formed to estimate in vivo sensitivity to 
insulin with the technique described by 
DeFronzo [245], with insulin (Actrapid® 
Human, Novo) infused i.v. at a constant 
rate of 56 mU/min per BSA (m2) calcu-
lated to achieve nearly complete suppres-
sion of hepatic glucose output [246]. The 
target plasma glucose concentration was 
5.1 mmol/l. The glucose disposal rate (M) 
was calculated as the amount of glucose 
(mg) taken up per kilogram (kg) of body 
weight per min during the last 60 min of 
the clamp study and is given in mg· kg-1 · 
min-1 /(100mU/ml). M/I thus represent 
the amount of glucose metabolized per 
unit of plasma insulin. The CV was 13.9%. 
The OGTT and the clamp procedure were 
separated in time from each other by one 
week.
Blood pressure (Study I and II)
Blood pressure was measured once in the 
right arm to the nearest 5 mm Hg in the 
supine position after 10 min rest. Systolic 
and diastolic blood pressure was defined 
as Korotkoff phases I and V, respectively.
Serum lipids (Study I and II)
Analyses of cholesterol and triglycer-
ide concentrations were performed on a 
Technicon Auto Analyzer type II. LDL 
cholesterol levels were calculated using 
Friedewalds formula:LDL= serum choles-
terol- HDL-(0.42 x serum triglycerides) 
[247]. 
Cardiac output (Study III)
The thermodilution catheters were in-
serted via the external or internal jugular 
veins and the tip of the catheter was ad-
vanced 3-5 cm beyond the point where 
pressure tracings indicated the passage of 
the pulmonic valve. 7.5-F pulmonary ar-
tery thermodilution catheters (AH-05050, 
Arrow international, Inc., Bernville, 
PA) sensor and the Siemens sirecust SC 
9000XL computer (Siemens, Denver, CO) 
were used to calculate CO from the modi-
fied Steward-Hamilton equation [64]. The 
injections were made by hand and always 
completed within 3 s. The injections were 
started as soon as the CO computer indi-
cated that the pulmonary artery tempera-
ture was stable, that is without taking into 
consideration the relationship between the 
injection and the respiratory cycle. The av-
erage result of five injections of 10 ml of 
iced 5% glucose solution was defined as 
the “true” CO. The computer integrates the 
temperature curve from the start of the fall 
in pulmonary artery temperature until the 
temperature has again risen to 60% above 
the nadir. 
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Invasive arterial blood pres-
sure (Study III)
A catheter with an arterial line primed 
with NaCl (0.9%) was positioned in the ra-
dial artery on the right wrist of all patients. 
A sterile line set with a disposable pressure 
biomedical sensor from BD critical care 
systems (Yishan ave. 7, Singapore) and a 
positive pressure flushing system was at-
tached to a Siemens HemoPod with a 3-m 
wired connection to a Siemens sirecust SC 
9000XL computer (Siemens, Denver, CO).
Glucagon (Study III)
Glucagon was assayed by a competitive 
radioimmunoassay (Euria-Glucagon®, Eu-
ro-Diagnostica) using a rabbit antiserum 
raised against a glucagon-albumin con-
jugate. Glucagon in standards and sam-
ples compete with 125I-labeled glucagon in 
binding to the antibodies in a two-step in-
cubation. 125I-glucagon binds in a reverse 
proportion to the concentration of gluca-
gon in standards and samples. Antibody-
bound 125I-glucagon was separated from 
the unbound fraction using double anti-
body solid phase. The radioactivity of the 
bound fraction was measured in a gamma 
counter [248].
Insulin and C-peptide  
(Study III)
Serum levels of insulin and C-peptide  were 
measured by an immunometric method 
with monoclonal antibodies (Modular E 
170, Roche Diagnostics Scandinavia AB).
NEFA (Study III)
Non-esterified fatty acid (NEFA), concen-
trations were determined colorimetrically 
with the NEFA-HR(2) kit (Wako Chemi-
cals GmbH, Germany) on a Thermo T20x-
ti instrument (Kone Oy, Finland). In brief, 
NEFAs were enzymatically converted to 
acyl-CoA and formed a purple complex 
with 4-aminantipyrine. The shift in color 
was spectrophotometrically detected at 
546 nm wavelength.
Arterial rings in organ baths 
(Study IV)
Femoral arteries from non-diabetic male 
Sprague-Dawley rats were carefully dissect-
ed free from surrounding tissue, removed 
and put into organ baths with KH solution. 
Circular segments (1-2 mm in length) of 
the artery were mounted on two thin met-
al holders, one of which was connected to 
a force displacement transducer (model 
FT03, Grass Instruments Co., Quincy, 
MA) and the other to a movable device 
that allowed the application of a passive 
tension of 5 mN. The tension was record-
ed on a polygraph (model 7B, Grass). The 
mounted vascular segments were kept in 2 
ml organ baths containing KH solution at 
37°C and continuously bubbled with CO2 
in O2 to maintain a pH of 7.4. After prepa-
ration, the vascular segments were allowed 
to equilibrate for 60 min. The contractile 
function of the vascular segments was first 
tested by administration of  K+-rich solu-
tion (127 mmol/l), prepared by replacing 
NaCl with equimolar amounts of KCl, and 
thereafter with phenylephrine (Phe; 10-5 
mol/l). Endothelium-dependent and -in-
dependent relaxations were determined 
by the administration of ACh and SNP, 
respectively. ACh and SNP were added to 
the organs baths at cumulatively increasing 
concentrations (10-9 – 10-5 mol/l,) during a 
stable contractile tone induced by Phe (10-
5mol/l). The relaxatory response following 
preincubation with a studied substance 
was always compared to the preceding 
control response in the same vascular seg-
Material and methods
36
ment. Exenatide (Neosystems, Strasbourg, 
France) was added to the organ baths at 
cumulative increasing concentrations (10-
13 - 10-8 mol/l) during baseline tension to 
evaluate contractile effects per se. The re-
laxant effects of exenatide, GLP-1 (7-36) 
(Neosystems, Strasbourg, France) and 
GLP-1 (9-36) amide (Bachem, Bubendorf, 
Switzerland) were evaluated by adding 
cumulative increasing concentrations (10-
13 - 10-8 mol/l) of these peptides to artery 
segments precontracted with Phe (10-5 
mol/l). The relaxant effect of GLP-1 was 
also tested in separate experiments togeth-
er with the DPP-4 inhibitor sitagliptin (5 
µM), which was  added 5 min before Phe-
induced contraction. Sitagliptin was also 
added during baseline tension and during 
Phe–induced contraction to evaluate any 
contractile or vasorelaxant effects per se. 
Finally, to investigate whether exenatide 
might co-activate the ACh relaxation, ex-
enatide was added in separate experiments 
to the organ baths 10 min before contrac-
tion with Phe. Thereafter the vascular seg-
ments were preincubated for 20 min with 
the triglyceride-rich emulsion Intralipid® 
(100 mg/ml) (Pharmacia-Upjohn, Upp-
sala, Sweden) diluted in KH solution to 
final concentrations of  0.5% and 1%,  cor-
responding to an approximate triglyceride 
level of  5 and 10 mmol/l, respectively. To 
examine any protective effect of exenatide 
against the triglyceride-induced endothe-
lial dysfunction, exenatide (final concen-
tration 2.5 nM) was administrated to the 
organ baths 20 min before the test of vas-
cular response to ACh and SNP.
Western blot (Study IV and V)
Western blotting was applied to quantify 
the total and phosphorylated eNOS (Ser 
1177) or Akt 1/2/3 (Ser 473) proteins in 
HCAECs (study V) and in aortas from 
Sprague-Dawley rats (study IV).
 HCAECs were grown and incubated 
in 100-mm Petri dishes. Cells were washed 
twice with PBS and lysed on ice in ice-
cold lysis buffer containing 1 mM sodium 
fluoride, 1 mM sodium orthovanadate, 1 
× protease inhibitor cocktail and 2% Tri-
ton X-100 in PBS (pH 7.5) for 30 min. The 
cell lysates were centrifuged (5,000 rpm, 
5 min, 4° C) and the supernatant was col-
lected. Equal amounts of protein (10-20 
µg) were subjected to SDS-PAGE under 
reducing conditions. The separated pro-
teins were electrotransferred onto nitrocel-
lulose membranes. The membranes were 
blocked in TBS-T (20 mM Tris-base, 137 
mM NaCl [pH 7.6] with 0.05% Tween 20) 
with 5% non-fat dry milk, followed by an 
overnight incubation with phospho-eNOS 
(Ser 1177) or phospho-Akt (Ser 473) anti-
bodies (1:500) in TBS-T/1% bovine serum 
albumin at 4° C. The membranes were 
extensively washed and subsequently in-
cubated with peroxidase-conjugated goat 
anti-rabbit IgG (1:10,000) in TBS-T with 
1% BSA for 1 h at room temperature. The 
membranes were extensively washed and 
the immunostained proteins were visual-
ized by ECL. The blots were stripped in 
Re-blot plus strong solution and probed 
with either anti-phospho-Akt 1/2/3 (Ser 
473) (1:500), anti-eNOS (1:500) or anti-
β-actin. The intensities of the bands thus 
obtained were quantified by densitometry 
(Gel DocTM, Bio-Rad laboratories, with 
software Quantity One). 
In study IV, frozen artery rings were 
thawed and homogenized in 100 µl buffer. 
The tissue was minced, homogenized and 
incubated on ice for 30 min and centri-
fuged (5,000 g, 5 min). Protein concentra-
tions were determined by the bicinchonin-
ic acid (BCA) method (Pierce Chemical 
Co., Rockford, IL). Phosphorylation of 
eNOS was examined by a phosphor-spe-
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cific antibody (at amino acid residue Ser 
1177) as a measure of eNOS enzymatic ac-
tivity (Santa Cruz) in a similar manner as 
described in study V.
NO (Study V)  
Direct measurement of NO release from 
HCAECs was performed using the cell-im-
permeable fluorescence indicator DAF-2 
as described [249]. Cells were incubated in 
12-well plates in the presence or absence 
of exenatide-4 (10 nM) or the inhibitors 
(1 mM L-NAME, 2 μM LY294002 or ve-
hicle) in serum-deficient medium for 48 
h. The cells were subsequently washed 
twice in Krebs-Ringer bicarbonate Hepes 
buffer (KRBH) buffer containing (in mM) 
135 NaCl, 3.6 KCl, 5 NaHCO3, 0.5 NaH2 - 
PO4, 0.5 MgCl2, 1.5 CaCl2 and 10 Hepes 
(pH 7.4), followed by an incubation with 
5 μM DAF-2 in 0.5 ml KRBH buffer for 2 
h at 37o C, using the eNOS substrate L-ar-
ginine (100 μM) as a positive control. The 
same concentrations of exenatide or the 
inhibitors were present in the correspond-
ing wells during the incubation. At the end 
of the incubation, the supernatants were 
transferred into black microplates and the 
fluorescence was measured with a micro-
plate reader (Infinite M200, TECAN) at 
an excitation wavelength of 488 nm and 
emission 515 nm. Results were normalized 
to the protein concentrations, determined 
using BCA kits, after the cells in each well 
were lysed in a lysis buffer containing (in 
mM) 80 Na2HPO4, 20 NaH2PO4, 100 Na-
Cl, 1% Triton X-100 (pH 7.5).
Akt activity (Study V)
Phospho-Akt was measured using Path-
scan phospho-Akt1 sandwich ELISA kit, 
according to the manufacturer’s instruc-
tions. The phospho-Akt specific ELISA 
detects Akt phosphorylated at serine 473. 
Samples were prepared from cells after a 
48 h incubation in the presence or absence 
of exendin-4. (7-36), and 100 µl aliquots of 
samples containing equal amount of pro-
tein were applied to each well.  
[3H]thymidine incorporation 
(Study V)
Rates of [3H]thymidine incorporation 
into DNA were analyzed as previously de-
scribed [250] as a measure of DNA syn-
thesis. In brief, HCAECs were grown in 
60-mm Petri dishes and cultured until 90 
% confluence. After serum starvation, cells 
were incubated in the presence or absence 
of kinase inhibitors (or vehicle) or exend-
in-4 for 48 h. Cells were pulsed with [3H]
thymidine (1 µCi/ml) 6 h prior to the end 
of the incubation. [3H]thymidine incor-
poration into DNA was measured using 
a microplate scintillation & luminescence 
counter (Wallac MicroBeta Trilux, Perk-
inElmer). Results were normalized to the 
protein concentrations of the samples, de-
termined using BCA kits.
Cell counting and viability 
(Study V)
HCAECs were incubated in the presence 
or absence of exenatide or inhibitors for 
48 h in serum-deficient medium as men-
tioned above. Cell number was manually 
counted in a hemocytometer and cell vi-
ability was assessed by Trypan blue exclu-
sion. 
Statistical analyses
All statistical analyses were performed us-
ing the statistical software package SPSS 
17.0 for PC. Tests were two-tailed, and a P 
value of less than 0.05 was deemed statisti-
cally significant.
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Distribution
The distribution of a continuous vari-
able was tested using Shapiro Wilk´s test. 
Skewed variables were log transformed to 
reach normal distribution (study I). Con-
tinuous variables are presented as means ± 
standard error of mean (SEM) or ± SD.
Correlation (study I and II)
Correlations between continuous base-
line variables were analyzed using Pearson 
product correlations.
Group comparisons 
(Study I, II, IV and V) 
Differences between groups were assessed 
by analysis of variance (ANOVA), one-way 
repeated measurement, followed by a Bon-
ferroni post-hoc test (Study I, II ,IV and 
V). In analyses using small sample sizes, 
results from ANOVA were checked with 
the Kruskal- Wallis and Mann-Whitney 
tests (study IV and V).
Logistic regression analysis 
(Study I)
Logistic regression analysis was used to as-
sess associations between baseline GLP-1 
variables and dichotomous-dependent 
variables. Potential associations were 
presented as odds ratio (OR) with corre-
sponding 95% confidence intervals (CIs) 
and tested with the Wald test. All analy-
ses were adjusted for age at baseline. In 
the multivariate models, adjustments 
were made for the possible confounding 
effects of M/I, plasma insulin and waist 
circumference regarding IGT and T2DM 
subjects. Goodness of fit was assessed by 
Hosmer-Lemeshow tests.
Survival analyses  
(Study I and II)
Cox´s proportional hazard regression 
analyses were used in the prospective anal-
yses. Hazard ratios (HRs) were obtained 
from the Cox`s models and are presented 
with their 95 % CI. Subjects were divided 
into quartiles according to their ΔGLP-1 
levels, and the time from baseline to event 
in the different groups of quartiles was 
compared with the use of the log-rank test 
and the results are presented as Kaplan-
Meier curves. Log-minus-log plots were 
performed to confirm proportionality of 
the hazards.
Mixed models (Study III)
Linear mixed repeated models, with sub-
jects as a random factor and with treat-
ment and time as fixed and repeated 
factors, were used to test the effects of 
treatment on continuous parameters. The 
unstructured covariance structure was 
chosen after comparison with other cov-
ariance structures. If an overall significant 
difference was present, pair-wise compari-
sons with Tukey´s least significant differ-
ence (LSD)  were performed to determine 
differences between active treatment and 
placebo.
Ethical considerations
Study I was approved by the ethics com-
mittee of the Faculty of Medicine at Upp-
sala University. Study II was approved of 
the central ethical review board in Stock-
holm and the Medical Products Agency 
(MPA). All human studies conformed to 
good clinical practice guidelines and fol-
lowed the recommendations of the Hel-
sinki Declaration. All patients provided 
written and oral informed consent before 
enrolment.
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Study IV was approved by the regional 
ethics committee for animal research and 
conforms to the Guide for the Care and 
Use of Laboratory Animals published by 
the National Institute of Health (NIH pub-
lication # 85-23, revised 1985).
Results
Study I
In this study, we demonstrated a reduced 
glucose-stimulated GLP-1 plasma con-
centration (ΔGLP-1) in the IGT group 
compared with the NGT group (figure 9). 
IGT was associated with lowered ΔGLP-1, 
lowest vs. the highest quartile (OR 0.3, CI: 
0.12-0.58), while no such association was 
discernable in the T2DM group (OR 1.0, 
CI: 0.38-2.86). No association was dem-
onstrated between IGT and fGLP-1 (OR 
1.4, CI: 0.78-2.53) or 60GLP-1 (OR 0.82, 
CI: 0.42-1.6). There was a significant as-
sociation between ΔGLP-1 and M/I in the 
T2DM group (r=0.38, P<0.01), with no 
such associations noticeable in the IGT 
(r=0.11, P=0.28) or NGT (r=0.10, P=0.16) 
groups (figure 10). During follow-up, 69 of 
294 NGT subjects (rate 2.6/100 PYAR), 42 
of 141 IGT subjects (rate 3.5/100 PYAR) 
and 32 of 74 T2DM subjects (rate 6.0/100 
PYAR) developed a CHD event. The me-
dian follow-up time was 12.0 years (range, 
0.2 to 13.8) with a total of 4,396 PYAR. No 
association was found between the low-
est vs the highest quartile of ΔGLP-1 and 
CHD, based on 143 individuals that devel-
oped CHD (HR 1.0, CI: 0.52-2.28). Unad-
Figure 9. ΔGLP-1 levels among NGT, IGT and T2DM subjects (Study I).  
IGT subjects demonstrate significant lower ΔGLP-1 levels compared to NGT subjects. *P = 
0.005. Bars indicate ±SEM.
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Figure 10. Scatter plots showing correlations between insulin sensitivity index (log M/I) 
and ΔGLP-1 at baseline separated by groups (Study I). 
 a) NGT (r=0.10, p=0.16), b) IGT (r=0.11, p=0.28) and c) T2DM (r=0.38, p<0.01). 
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justed Kaplan-Meier survival curves could 
not reveal any significant difference be-
tween quartiles of ΔGLP-1 regarding the 
risk for CHD. Neither fGLP-1 (HR 0.94, 
CI: 0.45-0.98) nor 60GLP-1 (HR 0.79, CI: 
0.37-1.6) correlated with CHD in the same 
follow-up period.
Study II
During the follow-up period, 16 of 290 
participants with NGT experienced a CHF 
event (rate 0.7/100 PYAR), as did 8 of 136 
(rate 0.8/100 PYAR) with IGT and 9 of 72 
(rate 1.7/100 PYAR) with T2DM (Figure 
11.). Although plasma GLP-1 concentra-
tions did not predict CHF (fGLP-1: HR 
0.98, 95% [CI 0.4-2.4], 60GLP-1: HR 1.1, 
95% [CI 0.4- 2.6], ΔGLP-1: HR 0.9, 95 % 
[CI 0.3–2.3]), there was an association be-
tween left ventricular diastolic function 
(E/A ratio) and fGLP-1 (r=0.19, P=0.001), 
60GLP-1 (r=0.20, P<0.001), and ΔGLP-1 
(r=0.18, P=0.004). When the associations 
between E/A ratio and GLP-1 were ana-
lyzed in the group that was investigated 
with echocardiography at baseline, these 
correlations remained significant. Interest-
ingly, we now found a stronger correlation 
between glucose-stimulated GLP-1 levels 
(60 min post challenge) and E/A ratio in 
the T2DM group (r=0.58, P=0.04).
Study III
Twenty male T2DM patients with known 
CHF were enrolled and completed the 
protocol. Baseline hemodynamic variables 
were consistent with decompensated heart 
failure with depression of CI and elevation 
of PCWP (Table 3). Exenatide compared 
Results
Figure11. Kaplan-Meier survival curves for participants free from subsequent CHF 
events during 9.8 years of follow-up (Study II). 
NGT (blue line), IGT(red line) and T2DM (green line). The risk of CHF was significantly higher in 
men with T2DM than for those with NGT (log rank test, P=0.02). 
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Parameter Value
Baseline hemodynamics
HR, (bpm) 73±4
RAP (mmHg) 9±1
PAP (mmHg) 28±2
PCWP (mmHg) 17±2
MAP (mmHg) 92±4
CO (L · min-1) 4±0.2
CI (L · min-1 · m-2) 1.8±0.1
SV (ml) 57±4
PVR (Wu) 3±0.4
SVR (dyne · s · cm-5) 1750±120
Baseline metabolic parameters
Plasma glucose (mmol/L) 6.6±0.3
Serum C-peptide (nmol/L) 1.2±0.2
Serum insulin (pmol/L) 440±120
Serum glucagon (pmol/L) 40±3
Plasma NEFA (mmol/L) 0.3±0.06
Plasma lactate (mmol/L) 1±0.09
Values are means ± SE. HR , heart rate; RAP, right atrial pressure; PAP, pulmonary arterial pres-
sure; PCWP, pulmonary capillary wedge pressure; MAP, mean arterial blood pressure; CO, car-
diac output; CI, cardiac index; SV, stroke volume; PVR, pulmonary vascular resistance; SVR, sys-
temic vascular resistance NEFA, non-esterified fatty acids. 
Results
with placebo increased CI by a maxi-
mum of 21% concomitant with lowering 
of PCWP and right atrial pressure (RAP) 
by 15%  and 17%, respectively (figure 12). 
The increase in CI was entirely contingent 
upon an increase in HR of 29% without 
any change in SV indicative of a positive 
chronotropic – but not inotropic – effect 
of exenatide in this acute setting. Glu-
cose concentrations were kept within the 
normoglycemic range during exenatide-
placebo infusions by adjustment of the in-
sulin-glucose infusion rate. There were no 
differences in glucagon and insulin con-
centrations during exenatide vs. placebo 
infusions. NEFA levels tended to rise dur-
ing both infusions but were significantly 
Results
Table 3. Baseline hemodynamic and metabolic parameters.
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Figure 12. Changes in CI, PCWP and HR during 6 hours of infusion of exenatide and 
placebo. 
Individual data. a, changes in CI during exenatide infusion. b, changes in CI during placebo 
infusion. c, changes in PCWP during exenatide infusion. d, changes in PCWP during placebo 
infusion. e, changes in HR during exenatide infusion. f, changes in HR during placebo infusion.
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higher during exenatide infusion com-
pared to placebo infusion (P=0.03; figure 
13). All participants completed the pro-
tocols. However, we observed ten adverse 
events during the exenatide infusion. Six 
of these were related to nausea and vomit-
ing, but two patients experienced a tempo-
rary increase in heart rate to such an extent 
that it required treatment with digoxin i.v. 
and in one patient an increase in systemic 
blood pressure necessitated a short term 
i.v. infusion with nitroglycerine.
Study IV
The main finding in this study is that both 
native GLP-1 (7-36) and its main metabo-
lite GLP-1 (9-36), but not exenatide, exert 
acute vasorelaxant effects in non-diabetic 
rat arterial rings in an ex vivo model. The 
primary aim was to investigate whether 
exenatide may confer protection against 
endothelial dysfunction, induced by a trig-
lyceride-rich fat emulsion (Intralipid®), in 
these vascular rings. However, this short-
term exenatide exposure did not protect 
against the triglyceride-induced endothe-
lial dysfunction. Immunoblotting data re-
vealed a single band with a molecular mass 
of 67 kDa, corresponding to the GLP-1 
receptor, demonstrating expression of the 
GLP-1 receptor in the artery. Immunob-
lotting also revealed a significant increase 
in eNOS enzymatic activity by Intralipid® 
incubation at both 0.5 and 2% of the emul-
sion. There was a clear tendency towards 
decreased Intralipid®-induced eNOS ac-
tivation by co-incubation with exenatide, 
although this effect did not attain statisti-
cal significance.
Study V
The main result of this study was that ex-
enatide, GLP-1 and GLP-1 (7-36) dose-
dependently enhanced HCAEC DNA syn-
thesis, as reflected by an increased rate of 
[3H]thymidine incorporation. Consistent 
with the stimulatory effect of exenatide 
on DNA synthesis, the total cell number 
was significantly increased in the presence 
of exenatide, thus confirming that DNA 
Results
Figure 13 . Effects of infusion with exenatide on NEFA  levels.  
Fatty acid levels are shown for exenatide and placebo over 6-hour double-blind infusions. 
Values are means±SE.* P= 0.03 (exenatide vs. placebo at 6 hours).
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synthesis was indeed followed by mitosis. 
Application of exenatide, GLP-1 (7-36) 
and GLP-1(9-36) to the HCAECs also elic-
ited a dose-dependent phosphorylation of 
eNOS at Ser-1177, thereby enhancing its 
catalytic activity. Exenatide GLP-1 (7-36), 
GLP-1 and GLP-1 (9-36) also augmented 
Akt phosphorylation , indicating activa-
tion of the enzyme. In the presence of a 
specific PI3K inhibitor, the effect of ex-
enatide, GLP-1 (7-36) and GLP-1 (9-36) 
on eNOS and Akt phosphorylation was 
abolished, indicating that eNOS phospho-
rylation induced by these peptides is me-
diated by PI3K-Akt-dependent signaling 
pathways. NO production stimulated by 
these peptides was completely abolished 
by either eNOS inhibitor (L-NAME) or 
PI3K inhibitor (LY294002) at the same 
concentrations that blocked phosphoryla-
tion of eNOS.
The stimulated DNA synthesis was fur-
ther evaluated in the presence of the eNOS 
inhibitor L-NAME and the PI3K inhibi-
tor LY294002. At the same concentrations 
that abolished phosphorylation of Akt and 
eNOS, the augmented DNA synthesis rate 
evoked by the peptides was completely 
abolished by L-NAME and suppressed by 
~ 70 % by the PI3K inhibitor. Finally, the 
increases in DNA synthesis and eNOS and 
Akt activation evoked by the peptides, were 
inhibited by PKA inhibitors and blocked 
by a GLP-1 receptor antagonist. A cartoon 
schematically depicting the intracellular 
chain of events, occurring between GLP-
1R occupancy to cell mitosis, is shown in 
figure 14.
General discussion
T2DM does not only increase the risk of 
incident CVD and associates with poor 
survival but is also an independent risk 
factor for CHF which is a malignant dis-
ease with a dire prognosis. To date it is, de-
spite considerable efforts, difficult to point 
out which of the existing anti-hyperglyc-
emic drugs that might be the treatment of 
choice targeting this increased risk of CVD 
and CHF. The most recent contribution to 
the armamentarium of antihyperglycemic 
treatment is incretin-based drugs. There is 
now a growing body of evidence that these 
General discussion
Figure 14. Schematic model of GLP-1-
stimulated proliferation of HCAECs.  
Stimulation of the endothelial cells with 
GLP-1/exendin-4 through occupancy of their 
cell surface GTP-binding protein-coupled 
receptor results in activation of adenylyl 
cyclase (AC, generating cAMP) and PI3K. The 
downstream PI3K effector, Akt, subsequently 
activates eNOS through phosphorylation, 
leading to NO-dependent proliferation of 
the cells.
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agents exert, besides their well known 
anti-hyperglycemic and weight-reducing 
properties [176, 180-182, 185, 186], direct 
effects on the endothelium, vasculature 
and the failing heart [194, 197, 206, 211-
214, 234-236, 251-256]. 
Our intention has been to investigate 
physiologic actions of incretins and phar-
macologic effects on the human heart and 
the vasculature and to reveal the under-
lying mechanisms behind these putative 
effects. To this end, we have employed 
several widely different methodological 
approaches, such as epidemiologic analy-
ses, a randomized clinical trial of interven-
tion and finally laboratory experimental 
investigations on animals and cells. In the 
cellular perspective, we gathered evidence 
for proliferative effects of native GLP-1 
(7-36), its degradation metabolite GLP-1 
(9-36) and its stable analog exenatide in 
HCAECs. These effects might serve to lim-
it the adverse consequences of the macrov-
ascular complications of diabetes as prolif-
erative dysfunction of endothelial cells is 
believed to contribute to premature devel-
opment of atherosclerosis [257]. More spe-
cifically, it is our belief that GLP-1 might 
“patch up” an early endothelial lesion oc-
curring in the highly pro-atherogenic dia-
betic milieu by rapidly covering it with en-
dothelial cells. Moreover, angiogenesis can 
be of potential clinical benefit in patients 
with ischemic heart disease or peripheral 
arterial disease, but neovascularization 
and vasoproliferation are also parts of the 
pathological processes leading to diabetic 
retinopathy [258]. However, it has to be 
noted that proliferation of endothelial cells 
is just one part of the complex sequence 
leading to angiogenesis [259]. 
In the ex vivo setting (paper IV), we 
found vasorelaxant effects of GLP-1 and its 
metabolite (9-36) at slightly supraphysi-
ological concentrations in a model of con-
duit arteries in non-diabetic rats, whereas 
no such effects of exenatide were noted 
suggesting vast differences in vasoactive 
Figure 15. GLP-1R-dependant and GLP-1R-independent effects. 
Model for explaining actions of GLP-1 (7-36) and GLP-1 (9-36) the vasculature and heart sug-
gesting GLP-1 receptor - depending and - independent effects.  Adapted from Circulation: Ban 
K, Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor - depend-
ent and  - Independent Pathways , Circulation, page 2340-2350, © (2008).
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potency between native GLP-1 and its 
metabolite on the one hand and the stable 
GLP-1 analogue exenatide on the other. 
This is supported by the finding that GLP-1 
(7-36) and GLP-1 (9-36) but not exenatide 
exert vasodilatation in mesenteric arteries 
in wild type and in GLP-1R-/- mice [197]. 
In our study (IV), exenatide failed to 
protect the arteries against triglyceride-
induced endothelial dysfunction. These 
findings might be explained by differ-
ences in affinity to the GLP-1 receptors 
in the endothelium but this could not be 
experimentally proven, due to difficulties 
to detect any significant binding of GLP-1 
in the endothelium. Another explanation 
for differences in cardiovascular effects be-
tween GLP-1 (7-36), GLP-1 (9-36) and ex-
enatide may be the receptor-independent 
actions of GLP-1 proposed by Ban et al. 
[197] (figure 15). The concept of GLP-1-
R-independent cardiovascular effects was 
further supported in a study where the 
GLP-1R antagonist exendin (9-39) inhibit-
ed hindquarter vasodilatation induced by 
exenatide but did not affect the mesenteric 
vasoconstriction in Sprague-Dawley rats 
[211]. 
Study III demonstrated potent acute 
effects of exenatide on critical hemody-
namic parameters in patients with T2DM 
hospitalized for decompensated heart fail-
ure. These effects appear to have occurred 
independent of changes in glycemia. The 
clinical impact of these findings, if any, is 
more difficult to interpret as we observed 
both positive, i.e. increase in CI and de-
creases of PCWP and RAP and potentially 
detrimental effects, i.e. increases in heart 
rate and NEFA levels). Recently published 
studies on a rodent model indicate that 
exenatide exerts tachycardia, vasocon-
striction in mesenteric arteries and va-
sodilatation in hindquarters [211, 226]. 
The results in these studies were consistent 
with the view that exenatide exerts cardio-
vascular effects, some of which involves 
sympathoadrenal activation [211, 226]. 
Therefore it seems prudent to believe that 
sympathoadrenal activation could have 
contributed to the increases in heart rate 
and NEFA levels that were observed in 
study III.
 In summary, the studies in this thesis 
focus on potential effects of GLP-1 and ex-
enatide in the vasculature and heart. We 
found that native GLP-1 (7-36), its main 
metabolite GLP-1 (9-36), and to a lesser 
extent exenatide, have direct effects on hu-
man coronary artery endothelial cells and 
rodent arteries in ex vivo settings. There 
are some contradictory findings in the 
preclinical experimental studies, i.e. paper 
IV and V. In study V, exenatide exerted 
activation of eNOS with a concomitant in-
crease of NO production but we could not 
detect any activation of eNOS by exenatide 
in study IV. These differences might sim-
ply be explained by the fact that the studies 
were evaluating effects on different species 
and models, i.e. in vitro studies of HCAE-
Cs  vs. ex vivo studies on rat femoral arter-
ies.     
We found potent hemodynamic ef-
fects of exenatide when administered to 
diabetic patients with worsened CHF.  The 
observed effects were both beneficial and 
potentially detrimental, but the drug (ex-
enatide) was fairly well tolerated in this 
group of hospitalized diabetic patients 
with decompensated CHF. Studies of the 
clinical implications of the use of exenatide 
in patients with decompensated heart fail-
ure are still in their infancy and therefore 
further prospective studies with clinical 
hard end-points, such as IHD morbidity 
and mortality, are very much needed.  Al-
though we have not compared the effects 
of native GLP-1 and exenatide in a clinical 
trial, our ex vivo study indicates that the 
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cardiovascular effects of GLP-1 (7-36) and 
GLP-1 (9-36) might be more pronounced 
than the effects of exenatide. These differ-
ences might be explained by both receptor 
dependent and receptor independent ac-
tions. Moreover, the molecular structure 
of exenatide is clearly different from that of 
native GLP-1; in fact, exenatide only share 
53% of the sequence homology of the na-
tive GLP-1.  A unifying scenario of GLP-1 
and exenatide cardiovascular effects is 
schematically proposed in figure 16.
Figure 16. Cardiovascular effects of GLP-1 and exenatide. 
Differences in cardiovascular actions between GLP-1 (A) and exenatide (B). Adapted from: 
Nyström T, The Potential Beneficial Role of Glucagon-like Peptide-1 in Endothelial Dysfunction 
and Heart Failure Associated with Insulin Resistance,  Horm Metab Res , page 601, © (2008), 
with permission from Georg Thieme Verlag KG.
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General discussion
Finally it seems prudent to believe 
that GLP-1 does not act as a risk marker 
for CVD. However, it must be noted that 
study II was somewhat under-powered to 
conclude that alterations in GLP-1 levels 
cannot be associated with the incidence of 
CHF. There is evidence that NO exerts fa-
vorable effects on left ventricular diastolic 
distensibility [97]. Therefore, our observed 
association between GLP-1 concentrations 
and diastolic function could be explained 
by alterations in NO production as we 
have demonstrated that GLP-1 increases 
NO production in HCAECs. This might 
be mediated by PI3K and Akt signaling 
pathways. As we cannot prove any cau-
sality of the association between plasma 
GLP-1 levels and diastolic function there 
is a need for further longitudinal studies in 
this field of research.
Future directions
So far there is evidence of GLP-1 action 
on vessels and heart. However, it is puz-
zling that there seems to be substantial 
differences between native GLP-1 and sta-
ble derivatives thereof, i.e. exenatide that 
only partially share amino acid sequence 
homology with the native GLP-1. There is 
also evidence for cardiovascular effects of 
the main metabolite GLP-1 (9-36) that are 
almost identical to those of GLP-1 (7-36). 
This could be explained by a specific GLP-1 
(9-36) receptor that mediates these cardio-
vascular effects (figure 15). The existence 
of such a receptor has already been sug-
gested by Ban and coworkers [221]. More 
detailed investigation and characteriza-
tion, e.g. sequencing and cloning of such a 
putative receptor could be of great value in 
the further exploration of this field of re-
search. Furthermore, the mitogenic effects 
of GLP-1 and exenatide should be evalu-
ated in retinal endothelial cells. Increased 
Future directions
proliferation of these cells could indicate 
an increased risk for retinopathy. 
As existing incretin-based drugs do 
not increase the GLP-1 (9-36) concentra-
tions, and taking into consideration the 
evidence of cardiovascular effects of this 
GLP-1 isoform, efforts aimed at finding 
drugs that increase both GLP-1 (7-36) and 
GLP-1 (9-36) may prove fruitful. Finally, it 
would be interesting to explore the puta-
tive effects of incretins on diastolic cardiac 
dysfunction in interventional prospective 
studies. 
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Limitations of the studies
I&II: These studies are based on elderly 
male patients, mainly Caucasians, 
which limits the generalizability of 
the results. In study II there were 
few events of CHF, which dimin-
ishes the power of the study. 
III:   Although a power calculation was 
made for this study, it was a small 
study with limited generalizability; 
the results cannot necessarily be 
extrapolated to a female, younger, 
non-diabetic or ethnically heteroge-
neous population receiving chronic 
treatment.
IV:    It would have been convenient, al-
though difficult, to include investi-
gations on small vessels (resistance 
or capillary vessels), and to ex-
pand the work to include studies of 
chronic exposure, in vivo settings, 
both genders, and diabetic models.
V:  We have only studied relative- 
ly short-term pharmacological ef-
fects of GLP-1, and derivatives 
thereof, on HCAECs in vitro from 
healthy subjects (non-diabetic in-
dividuals devoid of CVD). Fur-
ther studies on conditional GLP-
1R knock-out mice (soon to be 
acquired by our laboratory) and 
HCAECs in which GLP-1R is ei-
ther over-expressed or silenced (by 
siRNA) and under varying glycemic 
states  would have fortified the con-
clusions of this study.
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General Conclusions
In agreement with our hypothesis, we have 
found evidence of broad cardiovascular 
actions of GLP-1 and related peptides in 
a translational perspective; we were able 
to demonstrate cardiovascular effects of 
GLP-1 and its derivatives in human cellu-
lar models in vitro, rodent ex vivo model 
and a randomized clinical trial in T2DM 
patients and also found correlative asso-
ciations between  plasma GLP-1 levels and 
CVD in epidemiologic cohort studies.
We did not find any evidence of GLP-1 
as a predictor for CHD or CHF in a pop-
ulation-based longitudinal study of elderly 
men i.e. the ULSAM cohort. Nonetheless, 
we found a significant correlative associa-
tion between measures of cardiac diastolic 
dysfunction and GLP-1 levels in a cross-
sectional analysis of the ULSAM cohort.
The GLP-1 analog exenatide was found 
to exert potent and rapid hemodynamic 
effects in patients with T2DM hospital-
ized for CHF; exenatide increased CI and 
decreased PCWP and RAP significantly, 
but also increased heart rate and NEFA 
levels vs. placebo. As there seems to be 
both beneficial and potentially detrimen-
tal acute effects of exenatide in this group 
of patients, further prospective studies are 
needed. GLP-1 (7-36) and GLP-1 (9-36), 
but not exenatide, were found to exert 
vasorelaxant effects in femoral arteries ex 
vivo in non-diabetic rats. Exenatide failed 
to protect against triglyceride-induced en-
dothelial dysfunction in this system. 
Exenatide, GLP-1 (7–36) and GLP-1 
(9–36) promoted mitogenesis and en-
hanced eNOS and Akt activation in 
HCAECs in vitro. These effects were pre-
vented by PKA-, PI3K-, Akt- and eNOS-
inhibitors, suggesting that the incretins 
stimulate cell proliferation through PKA-
PI3/Akt-eNOS-dependent pathways. 
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